1st Annual
Neuroscience BioPartnering & Investment Forum
Focusing on Neurodegenerative Diseases and Pain Management

23rd February 2016
New York Academy of Sciences • USA

Conference Guide

www.sachsforum.com
Sachs Associates are delighted to welcome you to the:

1st Annual

Neuroscience BioPartnering & Investment Forum

Focusing on Neurodegenerative Diseases and Pain Management

23rd February 2016 • New York Academy of Sciences • USA

Sachs Associates, building upon its many years of expertise in organizing premier partnering and investor meetings in Europe and the United States, is proud to welcome you to the 1st Annual Sachs Neuroscience BioPartnering & Investment Forum being held on 23rd February 2016 at the New York Academy of Sciences. The forum is targeted at buy and sell side analysts from investment banks and funds and partnering executives from pharma.

Sachs Associates would like to thank our supporters and partners who have helped make this event possible.

---

General Information

• The registration desk is open from 7.30am on 23rd February although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session.

• One-to-one meetings
  Please bring with you a copy of your diary. Should you have any queries about your schedule, the laptop situated by the meeting tables is available for your assistance.

---

Request for Presentations

Please use the agenda to mark off presentations that you are interested in and email your request to Silvia@sachsforum.com after the conference. We will endeavour to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter. Please note that we DO NOT have copies of the slides that are shown during the conference.
Events Diary

For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Silvia Kar on Silvia@sachsforum.com

4th Annual
Cancer BioPartnering & Investment Forum
Focusing on Advances in Immuno-Oncology
24th February 2016 • New York Academy of Sciences • USA
The Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment. We expect around 250 delegates and around 30 company presentations by listed and private biotechnology companies seeking licensing & investment opportunities. Event’s networking will be powered by online One-2-One meeting system and dedicated meeting facilities to make the event more transactional and productive.

9th Annual
European Life Science CEO Forum & Exhibition
Partnering & Investing in Biotech & Pharma Industry
15th – 16th March 2016 • Hilton Zurich Airport Hotel • Switzerland
This event will be highly transactional, bringing together an exciting cross-section of venture-funded and small-cap companies with leading investors, pharma, and scientific thought leaders. We expect around 350 delegates and 80 presenting companies. Event’s networking will be powered by online One-2-One meeting system and dedicated meeting facilities to make the event more transactional and productive.

2nd Annual
Immuno-Oncology: BD&L and Investment Forum
3rd June 2016 • Hyatt Chicago Magnificent Mile • USA
The Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding & investment. We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment. Numerous networking opportunities available via an online One-2-One meeting system with dedicated meeting facilities to make the event more transactional.

4th Annual
MedTech & Digital Health Forum
for Technology & Healthcare Innovation
26th September 2016 • Congress Center Basel • Switzerland
The programme is designed to highlight the latest industry developments and showcase emerging and innovative technology companies seeking finance and partnerships. The delegates are comprised of Healthcare, MedTech, Healthcare IT, and Digital Health companies as well as consultants, bankers and corporate & financial investors. We expect over 200 delegates and 25 presenting companies plus demos.

16th Annual
Biotech in Europe Forum
For Global Partnering & Investment
27th – 28th September 2016 • Congress Center Basel • Switzerland
The forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry and is highly transactional. The Forum draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s bio industry, this event will once again be covered by our regular media partners. We expect over 600 delegates and 100+ presenting companies.
Andrew Singleton, **Laboratory Chief, National Institute on Aging NIH**

Dr. Singleton received his B.Sc. from the University of Sunderland, UK and his Ph.D. from the University of Newcastle upon Tyne, UK. Dr. Singleton’s research initially focused on genetic determinants of dementia, in particular Alzheimer’s disease and dementia with Lewy bodies. His postdoctoral studies were spent at the Mayo Clinic in Jacksonville Florida. Dr. Singleton moved to the National Institute on Aging at NIH Bethesda, MD in 2001 and became a principal investigator leading the Molecular Genetics Unit in 2002. In 2007 Dr. Singleton became a tenured senior investigator at the National Institute on Aging and in 2008 became the Chief of the Laboratory of Neurogenetics.

Dr. Singleton has published more than 400 articles on a wide variety of topics. His laboratory comprises ~50 staff, including four principal investigators and 3 group leaders. His laboratory works on the genetic basis of neurological disorders including Parkinson’s disease, Alzheimer’s disease, dystonia, ataxia, dementia, and amyotrophic lateral sclerosis. The goal of this research is to identify genetic variability that causes or contributes to disease and to use this knowledge to understand the molecular processes underlying disease.

Dr. Singleton currently serves on the scientific advisory board of the Michael J. Fox Foundation and the Lewy Body Dementia Association; he is a member of the editorial boards of Neurodegenerative Diseases, Neurogenetics, Movement Disorders, Brain (Associate Editor, Genetics), Lancet Neurology, the Journal of Parkinson’s Disease, the Journal of Huntington’s Disease and Annals of Neurology. Dr. Singleton was awarded the Boehringer Mannheim Research Award in 2005, the NIH Director’s Award in 2008, and the Annemarie Opprecht Award in 2008. In 2012 Dr. Singleton became the first person to win the Jay van Andel Award for Outstanding Achievement in Parkinson’s Disease Research.

Barry Kenny, **Chief Business Officer, Heptares Therapeutics**

Barry has over 25 years’ research and management experience in the pharmaceutical and biotechnology industry. He was previously Vice President, Drug Discovery at Takeda Cambridge with overall responsibility for IND discovery. Prior to this, he was Commercial Director at Paradigm Therapeutics where he was responsible for several company transforming deals, including the broad CNS collaboration with Takeda in 2005. He was also instrumental in the subsequent acquisition of Paradigm by Takeda in 2007. Barry co-founded Cambridge Drug Discovery (CDD) in 1997, and was Director of Business Development for Biofocus following its merger with CDD in 2001, establishing a wide range of international deals and collaborations. Before this, he was at Pfizer Central Research and was responsible for the successful discovery and progression of several drug candidates into clinical development. He also spent eight years at Syntex Research Scotland, where he completed his PhD and post-doctoral studies.

Beth Jacobs, **Managing Partner, Excellentia Global Partners**

Beth Jacobs is the Managing Partner of Excellentia Global Partners based in New York. EGP serves US, European and Asian-based clients on a range of engagements, raising capital, global strategy and growth through both organic and M&A approaches. She is active in scientific and social service not-for-profits, serving on the boards of The New York Academy of Sciences, as Governor and Executive Committee member, EF Foundation, Cambridge, Massachusetts, Harvard Kennedy School Womens Leadership Board, William J. von Liebig Foundation for Medical Research, Susan G. Komen Foundation – Global Ambassador, and as a special advisor to the Board of Positive Exposure.

Since 1982, Beth has built, managed and executed with some of the largest International Divisions in global investment banking, including Prudential Bache, Morgan Stanley, Shearson Lehman and ING Barings – Furman Selz. She held the position of Senior Vice President for Laureate Education (private), working across all business units in a corporate development role with a distinct focus on identifying and executing on opportunities in China. Beth received an MBA in international finance from American University in Washington, DC in conjunction with the School of Foreign Service, BA, cum laude, from Boston College and studied at Centre d’Etudes Internationale, Geneva, Switzerland diplomatic program.
Speakers

Bruce Leuchter, Managing Director, PJT Partners

Dr. Bruce Leuchter is a Managing Director at PJT Partners where he provides capital markets and M&A advisory services to companies in the life sciences industry with a focus on the biotechnology sector. Dr. Leuchter is a physician by training and Neuropsychiatrist by specialty. He completed residency training in Neurology and Psychiatry at New York Presbyterian Hospital / Cornell Medical Center and is a Diplomate of the American Board of Psychiatry and Neurology. Dr. Leuchter served as Director of Clinical Neuropsychiatry at Weill Medical College of Cornell University and maintains a faculty appointment of Clinical Assistant Professor of Psychiatry. Dr. Leuchter's financial services experience, prior to joining PJT Partners, includes roles in equity research and investment banking at Goldman Sachs and Credit Suisse, respectively. He joined Goldman Sachs in 2008 to spearhead a Global Investment Research initiative analyzing emerging biotechnology companies, and later joined Credit Suisse as an investment banker focused on the biotechnology sector. Given his background in neuroscience, he frequently advises companies developing technologies for diseases of the brain and nervous system. Dr. Leuchter serves as a member of the Scientific Advisory Committee for the Daedalus Fund for Innovation, a seed technology development program at Weill Medical College of Cornell University created to foster and expedite the development of early-stage translational research projects.

Carlos Buesa, CEO, Oryzon Genomics

Carlos Buesa is a specialist in the Biotech Industry. Dr Buesa got his PhD in Biochemistry from the University of Barcelona, Spain in 1993. He was post-doctoral fellow in the Faculty of Medicine at the University of Ghent in Belgium and later Senior Investigator at the Flemish Institute of Biotechnology (VIB). He has also taken the executive education programme (PADE) at the IESE Business School in Barcelona and several other additional educational programs in finances.

In 2000, he founded Oryzon. Since inception he has served as CEO and Chairman of the Board. Under his leadership the company has got +30M € in several funding rounds +31 M € in non dilutive funds. The company has evolved from a genomics platform based company to a epigenetic clinical stage company that went Public in the Madrid Main Stock Market in December 2015.

Oryzon’s forerunner program of LSD1 inhibitors for Oncology is in Phase I/IA. In April 20014, this program was licensed to Roche in a +$500 M deal which was lead by Dr. Buesa. Oryzon has moved to Phase I in 2016 a second molecule that targets also the epigenetic eraser LSD1 for the treatment of Alzheimer’s disease.

Charles Duncan, Managing Director, Senior Research Analyst, Biotechnology, Piper Jaffray

Charles Duncan, Ph.D., joined Piper Jaffray in 2012 as a managing director and senior research analyst focused on small- and mid-cap emerging growth biotechnology companies. Duncan brings more than 20 years of sell-side experience during which he has covered a broad range of biopharma companies, most recently serving as an analyst at JMP Securities since 2002. Previously, Duncan covered the sector at Dresdner Kleinwort Wasserstein, Vector Healthcare Group - Prudential Securities, Tucker Anthony Cleary Gull and Chatfield Dean & Co. Duncan has been recognized by industry sources, including the Financial Times and StarMine Analyst Awards, as being among the best analysts for his fundamental and timely analysis. Duncan began his career as a manager of clinical development at Global Drug Development, Inc., a pharmaceutical development consulting firm, and he also launched Infusion/Vision Medical, a venture-backed start-up medical device company. He is a graduate of the University of Wisconsin-Madison and holds a doctorate in pharmaceutical sciences with a concentration in neuropharmacology from the University of Colorado.
Daniel Alkon, CSO, Neurotrope, Inc.

Dr. Alkon has been the Chief Scientific Officer of Neurotrope Bioscience, Inc. since its inception. For much of his career, he has directed multidisciplinary neuroscience research at the NINDS, NIH, and at the Rockefeller Neurosciences Institute. After earning his M.D. at Cornell University and finishing an internship in medicine at the Mt Sinai Hospital in New York, he joined the staff of the National Institutes of Health. During his 30 year career at NIH, he became a medical director in the U.S. Public Health Service at the NINDS and chief of the Laboratory of Adaptive Systems. Dr. Alkon joined the Blanchette Rockefeller Neuroscience Institute as scientific director in 1999. He was named as recipient of the Toyota Chair in Neurodegenerative Disease Research for Distinguished Research at the Blanchette Rockefeller Neurosciences Institute in 2006 and is a professor of neurology in the West Virginia University School of Medicine.

Dr. Alkon’s laboratory at the Blanchette Rockefeller Neuroscience Institute conducts a multidisciplinary research program on the molecular and biophysical mechanisms of associative memory and memory dysfunction in psychiatric and neurological disorders, particularly Alzheimer's disease.

Dr. Alkon and his colleagues have discovered a convergence of memory physiology and pathophysiology that is guiding development of diagnostics and drug discovery with potential to treat neurodegenerative disorders (e.g. Alzheimer’s disease, stroke, and other diseases involving profound neuronal and synaptic loss. As an internationally recognized pioneer in research on brain-based neural networks and the molecular basis of memory, he has authored hundreds of scientific articles as well as several books including Memory Traces in the Brain by Cambridge University Press, and the popular book Memory’s Voice by Harper Collins.

David Baker, Chief Commercial Officer, Alcobra Ltd.

Mr. Baker joined Alcobra in January 2014 as the Chief Commercial Officer. Prior to joining Alcobra, he worked at Shire for 10 years, most recently as Vice President of Commercial Strategy and New Business in the Neuroscience Business Unit. In that role, he led the commercial assessment of neuroscience licensing opportunities, managed commercial efforts on pipeline CNS products, and led the long term strategic planning process. Previously, he served as Global General Manager for Vyvanse® where he led the launch of Vyvanse, led the launch of the adult indication for Vyvanse, and led global expansion efforts including successful establishment of a partnership in Japan and launches in Canada and Brazil. Prior to that, Mr. Baker served as Vice President of Marketing for all of Shire’s ADHD products. He has been directly involved with the commercialization of five approved ADHD medications.

From 1990 - 2004, Mr. Baker worked at Merck where he held positions of increasing responsibility in marketing, sales, market research, and business development. In addition to his knowledge and experience with CNS medications, Mr. Baker’s therapeutic expertise includes osteoporosis, migraine, and hyperlipidemia. He has been directly involved with the marketing of five medications with annual sales in excess of $1 billion each.

Ed Mascioli, Venture Partner, SV Life Science Advisors

Ed Mascioli has led several equity and debt healthcare venture capital financings, and has held leadership roles in both large pharmaceutical and small biotechnology companies. Ed is a Venture Partner of SV Life Sciences. Prior to this, he served as the Chief Executive Officer of Affinium Pharmaceuticals, Inc., leading its sale to Debiopharm International. Prior to Affinium, he served as a Vice President at Pfizer, Inc. and established and led its Rare Diseases Unit. Earlier, Dr. Mascioli was an Executive Partner of MPM Capital. Prior to joining MPM, he was an Executive Medical Director at Parexel, a leading international clinical research organization.

He started his career in academic medicine, being on the faculty of Harvard Medical School as an Assistant Professor of Medicine and on the staff of the Deaconess Hospital (now Beth Israel Deaconess Hospital) in Boston. He holds an M.S. in Nutritional Biochemistry and Metabolism from the Massachusetts Institute of Technology, an M.D. from the University of Massachusetts Medical School, and a B.A. in Biology, cum laude, from Brandeis University.
Elemer Piros, Senior Biotechnology Analyst, ROTH Capital Partners

Elemer Piros joined ROTH Capital Partners in February 2015 and is currently a senior research analyst covering the biotechnology sector. Prior to joining ROTH, Dr. Piros was the interim CEO of eMMUNITY, Inc, an immunotherapy startup company. Prior to the position at eMMUNITY, Dr. Piros was a publishing senior biotechnology analyst at Rodman & Renshaw and Burrill Securities, covering 80 companies developing products for CNS disorders, inflammation and the diagnosis and treatment of cancer.

Previously, Dr. Piros was a buy-side biotechnology analyst at Spear, Leeds & Kellogg, a wholly owned subsidiary of Goldman Sachs. From 1990 to 2000, Dr. Piros conducted academic research in the field of neuroscience, focusing on understanding the molecular mechanism of communication in the nervous system.

Dr. Piros was ranked as the #1 Biotechnology analyst by the Wall Street Journal in 2006 and by the Financial Times in 2010, both based on stock portfolio performance.

Emer Leahy, President and CEO, PsychoGenics, Inc.

Dr. Emer Leahy received her Ph.D. in Neuropharmacology from University College Dublin, Ireland, and her MBA from Columbia University. She has more than 25 years of experience in drug discovery and business development for pharmaceutical and biotechnology companies, including extensive knowledge of technology assessment, licensing, mergers and acquisitions, and strategic planning. Prior to her appointment as CEO, she was PsychoGenics’ Vice President of Business Development. In addition to the aforementioned, Dr. Leahy has served as Senior Vice President of Business Development at American Biogenetic Sciences, where she spearheaded contract negotiations and licensing agreements focusing on Alzheimer’s disease, epilepsy and other neurodegenerative disorders, and Vice President of Business Development, at AMBI Inc. Dr. Leahy served on the Emerging Companies Section Governing Board for the Board of Directors of the Biotechnology Industry Organization (BIO), and currently serves on the Business Review Board for the Alzheimer’s Drug Discovery Foundation and the Scientific Advisory Board of the International Rett Syndrome Foundation.

Eric Schaeffer, Senior Director Neuroscience External Innovation, Johnson & Johnson

Eric Schaeffer has more than 20 years of experience in pharmaceutical research and development, with a track record of delivering drug candidates to the clinic in both large and small company environments. Eric has an extensive background in the biology and pharmacology of CNS disorders including Alzheimer’s disease, major depressive disorder, bipolar disorder and schizophrenia. In his current role at Janssen R&D Eric is responsible for managing academic and biotech external partnerships in the areas of Mood Disorders and Alzheimer’s disease. Previous roles held by Eric include Senior Director of Neuroscience Discovery at Pfizer where he led discovery biology groups, Director of Neuropharmacology at CHDI where he was responsible for initiating and managing biotech and academic partnerships focused on Huntington’s disease and Director of Clinical Biomarkers at Bristol-Myers Squibb where he was responsible for developing the translational strategies for early clinical programs in the areas of schizophrenia, depression and neuromuscular disease. Eric received his PhD from the Albert Einstein College of Medicine, and did postdoctoral work at MIT and Rockefeller University prior to initiating a career in the pharmaceutical industry.
Eric Siemers, Distinguished Medical Fellow, Eli Lilly & Co.

Eric Siemers, M.D. is a Distinguished Medical Fellow of the Alzheimer’s Disease Global Development Team at Eli Lilly and Company. He earned his MD with highest distinction from the Indiana University School of Medicine in 1982. After an internship in the Department of Internal Medicine at the Indiana University School of Medicine, he completed his residency in the Department of Neurology in 1986. Prior to joining Lilly, he founded and headed the Indiana University Movement Disorder Clinic; his previous research included investigations of Parkinson’s disease and Huntington’s disease, and he established one of the first centers for surgical PD treatments in the US. Dr. Siemers currently directs late stage clinical research efforts at Lilly concerning investigational treatments for Alzheimer’s disease, and is more broadly involved with other neurological indications such as Parkinson’s disease. Major research interests include the use of biomarkers in investigational drug research and the development of trial designs that broadly characterize the effects of investigational drugs on chronic diseases. Dr. Siemers is a founding member of the Alzheimer’s Association Research Roundtable and is currently serving as Chair. He is a member of the Steering Committee for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), which is funded by the National Institute on Aging and a consortium of pharmaceutical companies. He served as the chair of the Industry Scientific Advisory Board for ADNI in 2007 and previously served as a member of the Resource Allocation Request Committee. Dr. Siemers participated as a member of the NIA working group that proposed criteria for preclinical Alzheimer’s disease in 2011. He is a past member of the Board of Directors of the American Society of Experimental Neurotherapeutics.

Ginger Johnson, Vice President, Defined Health

Ginger Johnson, Ph.D. is Vice President and CNS Practice Lead for Defined Health, where she manages core opportunity assessments and strategic consulting projects. Her background spans both the science and business of healthcare, ranging from basic scientific research to private equity investment and corporate development. Ginger was Vice President, Corporate Development at Skila (an e-Health company), and the Director of Life Science Research at Chase Capital Partners private equity firm (now JP Morgan Partners). Ginger was Associate Director of the Center for Biotechnology at Northwestern University and spent eight years in basic and applied scientific research, primarily in the field of Alzheimer’s Disease, at the National Institute of Mental Health. Ginger holds B.S. in Molecular Biology from the University of Tennessee and a Ph.D. in Genetics from the George Washington University.

Gerald Commissiong, President & CEO, Amarantus BioScience Holdings, Inc.

Mr. Commissiong is President & CEO, Co-Founder and a member of the Board of Directors of Amarantus Bioscience Holdings, Inc. Mr. Commissiong has been responsible for leading the Company’s strategic transactions, licensing, research collaborations, mergers and acquisitions, and fund raising. He has raised over of $40 million to acquire and develop assets to build a robust therapeutics and diagnostics pipelines across neurology, regenerative medicine and orphan diseases — with a particular focus on Parkinson’s disease. Prior to becoming CEO in October 2011, Mr. Commissiong was the Chief Operating Officer. Prior to co-founding Amarantus with his father Dr. John Commissiong, Mr. Commissiong played professional football for the Calgary Stampers of the Canadian Football League. Mr. Commissiong received a B.Sc. in Management Science and Engineering with a focus on Financial Decisions from Stanford University.
Hendrik Liebers, CFO, Probiodrug AG

Dr Hendrik Liebers has been Chief Financial Officer of Probiodrug since 2007.

Prior to joining the company as CFO in 2007, Dr Liebers spent nine years with several private equity and venture capital firms with a focus on biotech, pharma, medtech, agro-biotechnology and fund in fund investments. He successfully executed numerous private placements, trade and asset sales, fund in fund investments, mergers and acquisitions as well as licensing and co-development transactions in Europe and the U.S. From 2004 to 2007 he was Head of Life Science at IBG, and was responsible for IBG’s Life Science team and activities. From 1998 to 2004 he held several positions with Corporate Finance Holding GmbH (CFH), lastly as Investment Director. Dr Liebers has served on numerous boards, among them as Vice Chairman of Probiodrug’s supervisory board until 2007.

He holds a diploma in economics from University of Leipzig, a diploma of biology from Eberhard Karls University of Tuebingen, and a Dr. rer. med. from the Medical Faculty of the University of Leipzig.

Jak Knowles, Managing Director and Vice President Medical and Scientific Affairs, CureDuchenne Ventures

Dr. Jak Knowles joined CureDuchenne in 2015 as the Managing Director of CureDuchenne Ventures and the Vice President of Medical and Scientific Affairs for the CureDuchenne Research Foundation. Jak has had a career in healthcare spanning over a decade with the last five years focused in biotech venture capital and finance. Most recently, Jak was as an investment professional in the Boston office of MPM Capital ($2B AUM) where he worked within the BioVentures Asset Management team starting early-stage companies focused on developing curative therapeutics across a wide spectrum of indications. Prior to MPM, Jak worked in New York as a biotechnology equities analyst within the investment bank JMP Securities, and with Burrill & Co., a life sciences VC firm. Jak began his post-graduate business career working in health and life sciences consulting practice of Oliver Wyman where he helped implement value-based transformation of hospital systems and physician practices through re-designing care-models, implementation of electronic clinical decision support, and structuring reimbursement around patient centric care. Jak has a medical degree from Stanford University where he graduated with honors in biomedical research, and a B.S. in biology from Binghamton University. Jak has authored over a dozen publications from research performed at the Sloan Kettering Cancer Center, Stanford University, and during a NIH post-doctoral surgical research fellowship. Currently, Jak serves on the Board of Directors for Myotherix, RASRx, and Bamboo Therapeutics.

Jeffrey Davis, COO, Abeona Therapeutics, Inc.

Jeffrey B. Davis became a director in March 2006. Since January 19, 2015, Mr. Davis is our Chief Operating Officer. Mr. Davis was our Chief Executive Officer from December 26, 2007 until September 19, 2014. Mr. Davis became Acting Chief Financial Officer, Treasurer and Secretary on November 1, 2013 through September 19, 2014. Previously, Mr. Davis served in a variety of senior investment banking and management positions, and in senior management at a publicly traded healthcare technology company. Prior to that, Mr. Davis was an investment banker with various Deutsche Bank banking organizations, both in the U.S. and Europe. Mr. Davis also served in senior marketing and product management positions at AT&T Bell Laboratories, where he was also a member of the technical staff, and at Philips Medical Systems North America. Mr. Davis is currently on the board of Uluru, Inc., a public biotechnology company. Mr. Davis holds a B.S. in biomedical engineering from Boston University and an M.B.A. degree from the Wharton School, University of Pennsylvania.
Speakers

Jennifer Farmer, Executive Director, Friedreich’s Ataxia Research Alliance

Jennifer Farmer is the Executive Director of the Friedreich’s Ataxia Research Alliance. Jennifer has a Master’s degree in Genetic Counseling and prior to joining FARA she worked at the University of Pennsylvania and Children’s Hospital of Philadelphia. Jennifer’s developed a special interest in neurogenetic conditions and then went on to establish and coordinate clinical and research programs for individuals and families diagnosed with Friedreich Ataxia (FA) and related neurodegenerative diseases. Specifically, she is one of the founders and the coordinator for the Collaborative Clinical Research Network in FA. This network is in its 10th year with natural history data, clinical outcome measures, biomarkers and biorepository on >850 FA subjects. In addition, Jennifer established FARA’s Patient Registry in 2006. This is a patient driven registry that has >2500 participants worldwide. In her current role at FARA as Executive Director, she helps to carry out the strategic mission of the organization through administering FARA’s research grant, scientific conference, patient registry, and education and awareness programs.

Jerry McLaughlin, President & CEO, AgeneBio, Inc.

Jerry McLaughlin has served as our President and Chief Executive Officer since June 2014. He has 25 years of executive, operational and commercial leadership experience in the biopharmaceutical industry. Prior to joining AgeneBio, he served as the Senior Vice President and Chief Commercial Officer of NuPathe Inc. until the company was acquired by Teva Pharmaceuticals Industries Ltd. in 2014. Mr. McLaughlin served in a variety of commercial leadership roles at Merck from 1990 to 2001 and Endo Pharmaceuticals from 2001 to 2007. He holds a BA in Economics from Dickinson College and an MBA from Villanova University.

Jim Ray, Institute Head, Neuroscience, The Neurodegeneration Consortium, MD Anderson

My current role is the Director of the Neurodegeneration Consortium (NDC), a non-profit drug discovery center comprised of leading researchers in the field of neurological disorders at Baylor College of Medicine, MIT, and the Whitehead Institute combined with a professional small molecule drug discovery engine at MD Anderson. Our goal is to develop novel therapies that will slow, stop, or reverse the progression of Alzheimer’s disease, and we have developed a portfolio of 10 early stage drug discovery projects to support that mission. Prior to joining the NDC, I was Director of CNS Research at Takeda Pharmaceuticals, where we developed clinical candidates for schizophrenia, autism, and Parkinson’s disease. This role at Takeda resulted from my time as Senior Director at the startup company Envoy Therapeutics, which Takeda acquired, where we developed a genomics-based novel target identification and validation platform along with a pipeline of lead optimization projects. Before joining Envoy I spent 11 years at Merck, leading drug discovery projects in AD and musculoskeletal disorders.

Joel Braunstein, CEO, C2N Diagnostics

Dr. Braunstein is a cardiologist and internist. He is a Co-Founder of C2N and has been its CEO since inception. Dr. Braunstein has co-founded and played a senior operating role in numerous emerging life sciences companies. He is Founder and Managing Director of LifeTech Research (LTR) and its investment affiliate, LifeTech Development Partners, LP. Beside C2N and LTR, he is a corporate director at Tivorsan Pharmaceuticals, Centegen, NexGen Medical Systems, and 3PrimeDx. Dr. Braunstein received his M.D. with highest distinction from Northwestern University Medical School in 1996. Subsequently, he trained in internal medicine at the Brigham and Women’s Hospital, Harvard Medical School until 1999, and as a Fellow in Cardiovascular Medicine and Robert Wood Johnson National Clinical Scholar at the Johns Hopkins Medical Institutions. Additionally, he completed an M.B.A. with management focus in 2004 and maintained an adjunct cardiology faculty position at Johns Hopkins University. In 2010, he was named a Distinguished Alumnus of the University.
John Kaiser, Chief Business Officer, Cerecor, Inc.

Mr. Kaiser has served as our Chief Business Officer since September 2015, as our Chief Commercial Officer from February 2014 to September 2015, and as our Vice President, Commercialization and Business Development from October 2012 to February 2014. Prior to joining our company, Mr. Kaiser served as Senior Director of Business Development & New Ventures of MedAvante, Inc., a global provider of centralized expert psychiatric and neurocognition rating and monitoring services to the pharmaceutical, biotechnology and medical device industries, from July 2011 to September 2012. Mr. Kaiser also founded Denysias Bioscience, LLC, a biopharmaceutical company focused on developing new therapies for neuropsychiatric disorders, where he served as Chief Executive Officer from February 2010 through June 2012. Mr. Kaiser has served as President of Kaiser & Associates Consulting, a boutique consulting firm providing expertise to the biopharmaceutical industry, since November 2009. From February 2008 through November 2009, Mr. Kaiser served as Vice President of Commercial and Business Development at ACADIA Pharmaceuticals Inc., or ACADIA, a specialty pharmaceutical company. Prior to ACADIA, Mr. Kaiser held numerous positions of increasing responsibilities at Eli Lilly that spanned more than 25 years. At Lilly, Mr. Kaiser held various assignments in sales, marketing and general management in the US and Europe. For nearly 20 years Mr. Kaiser’s experiences were concentrated within Neuroscience having served as global commercial lead for Prozac, having contributed to the launch of Zyprexa ex-US, and having led the global strategic commercialization efforts for Cymbalta in depression and pain. Mr. Kaiser also led the strategic marketing efforts for the companies CNS development portfolio and co-led the development and execution of the companies CNS strategy. Mr. Kaiser received his B.S. in Pharmaceutical Sciences from the James L. Winkle College of Pharmacy at the University of Cincinnati.

John Renger, Associate Vice President, Target Acceleration & Translational Capabilities Neuroscience, Merck

John is currently leading an end-to-end discovery-to-development group, Target Acceleration and Translational Capabilities within Merck Research Laboratories, West Point, PA. Prior to joining Merck, Dr. Renger was a Merck-MIT Fellow at the Center for Learning and Memory, Massachusetts Institute of Technology, where his work focused on understanding the neurophysiological basis of memory-related changes in the brain. Before MIT, Dr. Renger worked at the Brain Science Institute, RIKEN, Japan. There he studied the neurogenetic basis of cortical neuron plasticity in the visual area of the brain to reveal the genetic basis of synaptic competition in the mammalian central nervous system. Dr. Renger earned his bachelor’s degree in biology from the University of Iowa and followed with his Ph.D. degree also from UI. His graduate work established a basis for understanding genetic control of synaptic plasticity changes in learning and memory mutants discovered in Drosophila. With a diverse neuroscience background, Dr. Renger has been successful in leading teams that have brought forward multiple preclinical candidate molecules across more than 8 mechanisms of action and in multiple CNS diseases. He has championed clinical translational efforts across disease targets and has worked on multiple teams that have designed clinical PET tracers. He initiated and lead the translational EEG sleep research lab at MRL that has been key for the innovative discovery, development and ultimate FDA/ PMDA approvals of the dual orexin antagonist Belsonor (suvorexant); the first and only orexin receptor antagonist to be launched in the US and Japan. This achievement represents the discovery of a newly approved class of CNS medication and is the first new mechanism to specifically target sleep neural networks within the brain. For his pioneering translational work, Dr. Renger is one of a select few scientists within Merck to have received the Merck Presidential Fellowship Award.
Speakers

Kathryn Gregory, *Executive Director, Licensing & Business Development*, Purdue Pharma L.P.

Kathryn J. Gregory, MBA, leads the identification, evaluation and negotiation of new business development opportunities including alliances, collaborations, mergers and acquisitions at Purdue Pharma L.P.

Ms. Gregory has more than 20 years of biotechnology and pharmaceutical industry experience and comes to Purdue Pharma from Shire where she was responsible for business development transactions for the Neuroscience and Ophthalmology business units. Ms. Gregory’s background includes international business development, mergers and acquisitions, licensing, marketing, strategic sourcing and procurement.

Prior to Shire, Ms. Gregory held various executive business development leadership positions at a variety of pharmaceutical and biotechnology companies, including PhaseBio Pharmaceuticals, Teva Pharmaceuticals, Neose Technologies, Cytel Corporation and Genia Sicor Pharmaceuticals.

Ms. Gregory earned a Master’s of Business Administration degree from Pepperdine University and a Bachelor’s of Science degree from the University of California, Berkeley.

Kees Been, *CEO, Lysosomal Therapeutics*

Kees Been is CEO of Lysosomal Therapeutics Inc (LTI), an early-stage biotech company which is leveraging the genetic link between Gaucher’s and Parkinson’s disease and is developing compounds that modulate lysosomal enzyme activity as potentially breakthrough classes of agents for GD and PD. He was formerly CEO of EnVivo Pharmaceuticals (now FORUM Pharmaceuticals) where he successfully built a neuroscience biotech company, recognized for its pipeline of NCE drug compounds, its lead compound in Phase 3 clinical testing for cognition improvement in Alzheimer’s and schizophrenia.

While a Biogen, he directed the Oncology Business Unit which was sold to Idec, and, as Senior Vice President of Business Development.

Kees holds an MBA degree from INSEAD in France and graduated from the University of Agriculture in Holland, majoring in Molecular Biology and Process Engineering.

Kees likes to spend his weekend mornings flying his single-engine airplane, exploring local airports in the New England area that offer brunch menus.

Kiran Reddy, *Venture Partner, Clarus Ventures, LLC*

Kiran Reddy is a Venture Partner at Clarus Ventures where he focuses on new company formation and due diligence. Prior to Clarus, Kiran was at Biogen as part of the Corporate Strategy leadership team where he focused on sourcing new technologies and product opportunities to support the Company’s growth via acquisitions, partnerships, and equity investments. Prior to Biogen, Kiran was an Associate Partner at Third Rock Ventures. He supported and managed various portfolio companies in addition to focusing on new company formation and new investments. He was part of the founding team and interim Chief Business Officer for SAGE Therapeutics through its IPO, and co-inventor of SAGE-547 the Phase 3 program for the rare epilepsy disorder refractory status epilepticus. Kiran was part of the team that launched Foundation Medicine, and he has served as a Board Observer for Alnara Pharmaceuticals, Rhythm Pharmaceuticals, and Panoptica Pharmaceuticals. Before Third Rock Ventures, Kiran was a management consultant at the Lewin Group within in the biotechnology and pharmaceutical practice, and advised clients on clinical development and commercial strategy. Kiran holds MD and MBA degrees from Georgetown University. He completed his internship in medicine and his neurology residency at Harvard / Massachusetts General Hospital and is a board certified neurologist. Kiran was previously a Howard Hughes science fellow, and has authored several peer-reviewed scientific papers in the field of neuroimmunology and neurodegenerative diseases.

SACHS

ASSOCIATES

1st Annual
Neuroscience BioPartnering & Investment Forum
Speakers

Liam Ratcliffe, Managing Director, New Leaf Venture Partners

Liam Ratcliffe is a Managing Director at New Leaf Venture Partners, and concentrates on biopharmaceutical investing. Liam joined New Leaf in September 2008. Liam previously served as Senior Vice President and Development Head for Pfizer Neuroscience, as well as Worldwide Head of Clinical Research and Development. Additional positions during his 12 years at Pfizer included Vice President of Exploratory Development for the Mid West region (based in Ann Arbor, MI), and Head of Experimental Medicine at Pfizer’s Sandwich, UK Laboratories. As Head of Neurosciences, Liam was responsible for the development of several successful late-stage projects and marketed products, including Lyrica, Chantix and Geodon. In previous roles, he gained extensive experience in early drug development and translational research across multiple therapeutic areas, including inflammation, pain, cardiovascular disease, infectious diseases and genito-urinary medicine.

Liam began his career in the pharmaceutical industry in a medical marketing role at Roche in South Africa. He received his M.D. degree and Ph.D. degree in immunology from the University of Cape Town and his M.B.A. degree from the University of Michigan. Liam completed his internal medicine training and fellowship in Immunology at Groote Schuur Hospital and associated teaching hospitals in Cape Town, South Africa.

Liam also serves on various industry panels, including the Leadership Counsel of the University of Michigan Life Sciences Institute, the Advisory Council of the Keck Graduate Institute, the Life Sciences Advisory Panel of Frankel Consulting and the Pfizer External Advisory Panel for Ophthalmology, the AstraZeneca External Advisory Panel for Research & Development Strategy and Anti-Infectives.

Liam serves on the board of the following companies: • Afferent Pharmaceuticals • Arvinas, Inc. • Calchan Ltd. • Deciphera Pharmaceuticals • Edge Therapeutics • Karus Therapeutics • Unum Therapeutics

Mark Day, Executive Director, Head of External Research & Scouting, Alexion Pharmaceuticals, Inc.

Mark Day is the Head of new group at Alexion Pharmaceuticals, called External Research and Scouting. Our focus is to build and run an external research engine to help drive our pipeline moving forward. Mark’s background spans across BD (Alexion, BMS), Academic Science (Adjunct at Yale), Drug Discovery (Alexion, GSK, Wyeth) & Translational Medicine (Wyeth and Abbott). At BMS he was involved in several deals and scouted and championed the acquisition of iPierian which closed on April 29th 2014. Mark Day has published over 60 peer-reviewed manuscripts in leading journals including Nature & Science. Mark remains totally committed to pushing the envelope on how to increase the PTS of drug discovery and development across all rare diseases.

Mark Mintun, President & Chief Medical Officer, Avid Radiopharmaceuticals, Inc.

Mark A. Mintun, M.D., is President and Chief Medical Officer of Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly & Co. In this position he is responsible for the overall strategy, discovery and clinical development of imaging diagnostic drugs. Dr. Mintun earned his undergraduate degree in Chemical Engineering from Massachusetts Institute of Technology and his medical degree from Washington University. He completed a nuclear medicine residency and neurology research fellowship at Mallinckrodt Institute of Radiology and Washington University and continued there as faculty. His research career has focused on the development of new PET tracers, applications and methodologies in neurology, psychiatry and oncology. Prior to joining Avid Radiopharmaceuticals in 2010, Dr. Mintun was Vice Chair of Radiology at Washington University. In that position, he directed several programs including the Center for Clinical Imaging Research and the NINDS Center Core for Brain Imaging as well as managed the neuroimaging research efforts in the Alzheimer's disease research center.
Speakers

**Maurice Zauderer, President and Chief Executive Officer, Vaccinex, Inc.**

Dr. Zauderer has held senior faculty positions in Immunology at Columbia University and at the University of Rochester Cancer Center. Dr. Zauderer served on multiple peer review study sections at NSF, NIH and National Multiple Sclerosis Society and was Associate Editor of the Journal of Immunology in 1987-89 and again 1994-99. Among his research contributions in Cellular and Molecular Immunology, he was among early investigators to identify subsets of helper T cells and is the inventor of core technologies for construction of representative cDNA libraries in vaccinia virus. He went on to develop applications of that technology for identification of therapeutic targets in cancer and to select fully human monoclonal antibodies against such targets. In 1997, Dr. Zauderer founded Vaccinex, a biotechnology company developing products based on these discoveries. Dr. Zauderer holds a Ph.D. in cell biology from the Massachusetts Institute of Technology. He has served as President and CEO of Vaccinex since its inception.

**Martin Heidecker, Managing Director, Boehringer Ingelheim Venture USA, Inc.**

Martin joined the Boehringer Ingelheim Venture Fund (BIVF) in 2010 to invest in early innovative therapeutic life science companies. In October 2013, Martin established the US-office of BIVF in Cambridge, MA, where he is focusing on biotech seed-investments. He has 15 years of investing and commercial experience in both venture capital and global pharma companies. He serves as board member of AMP Therapeutics in Leipzig, ArmaGen in Calabasas, CA, 121bio in Cambridge, MA and Sentien Biotech, Medford, MA.

**Maxim Jacobs, Senior Healthcare Analyst, Edison Investment Research**

Maxim is Senior Healthcare Analyst at Edison Investment Research where he covers companies from all sub-sectors of healthcare. He joined Edison from Guidepoint Global, where he was a director of survey and tracker research, conducting extensive primary research across healthcare markets. He also brings more than 15 years’ experience in equities to the healthcare team. Previously he was a senior healthcare analyst and therapeutic sector head at Ridgemark Capital and Broadfin Capital, and a healthcare analyst at Mehta Partners. Maxim is a CFA charter holder and graduated magna cum laude with a BA in Economics from the University of Pennsylvania.
Michael D. Ehlers, Group SVP, Head, BioTherapeutics R&D, CSO, Neuroscience & Pain, Cambridge & Boston Site Head, Pfizer, Inc.

Michael Ehlers is Senior Vice President for BioTherapeutics Research & Development and Chief Scientific Officer for Neuroscience & Pain at Pfizer, Inc. Dr. Ehlers grew up rural Nebraska and earned his bachelor’s degree in chemistry from Caltech. He holds M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine. Prior to joining Pfizer in 2010, Dr. Ehlers was the George Barth Geller Professor of Neurobiology and an Investigator of the Howard Hughes Medical Institute at Duke University Medical Center, where he pioneered studies on neuronal organelles and the trafficking of neurotransmitter receptors. Dr. Ehlers’ current research focuses on the interface between neuronal cell biology, the plasticity of neural circuits, and neuropsychiatric disease. At Pfizer, Dr. Ehlers oversees the operation and function of Pfizer’s Cambridge and Boston research sites. He has led groups that have brought 21 compounds into phase 1 and phase 2 clinical development in Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, schizophrenia, hemophilia, sickle cell disease, and other disorders. In addition to neuroscience, Dr. Ehlers directs discovery and early clinical development activities in rare disease, is responsible for a network of collaborations with major academic institutions and NIH covering all therapeutic areas, and leads global activities in biologics design, synthesis, and production. He is the recipient of numerous awards including the 2003 Eppendorf & Science Prize in Neurobiology, the 2007 John J. Abel Award in Pharmacology, the 2007 Society for Neuroscience Young Investigator Award, an NIMH MERIT Award, and the 2009 National Alliance for Schizophrenia and Depression Distinguished Investigator Award. He received the 2008 Breakthrough Research Award of the North Carolina Biotechnology Center given to a single scientist in North Carolina. In 2013 he became the 11th recipient of the Thudichum Medal of the Biochemical Society of the United Kingdom an award inaugurated in 1974 to honour eminent scientists who have made outstanding contributions to neurochemistry and related subjects, whose recipients include two Nobel laureates. Dr. Ehlers has authored over 90 scientific papers, has served on the Editorial Boards of Annual Reviews in Medicine, Annual Reviews in Pharmacology and Toxicology, the Journal of Neuroscience, the Journal of Biological Chemistry, and Molecular and Cellular Neuroscience, and sat on advisory committees of the National Institutes of Health. He is a member of the PhRMA Foundation Basic Pharmacology Advisory committee, the Janelia Research Institute Advisory Committee, the McKnight Endowment Fund for Neuroscience Board, and the World Economic Forum Global Agenda Council on Brain Research. He serves on the advisory boards of several private foundations, and has advised major pharmaceutical, venture, government, and biotech organizations.

Murali Gopalakrishnan, Senior Director, Search & Evaluation Neuroscience, AbbVie, Inc.

Murali Gopalakrishnan is currently Senior Director and Head, Search & Evaluation Neuroscience, at AbbVie, North Chicago, Illinois, USA.

Murali joined Abbott/AbbVie in 1993 and subsequently held various positions of increasing responsibility leading research programs and research teams in neuroscience, pain, renal and urology - advancing multiple clinical candidates across these therapeutic areas. He has extensively published in scientific journals and was inducted to the Volwiler Research Society in 2002. From 2009-2013, Murali took on the role as Head of the then newly formed Global External Research group in Discovery, leading a scouting group focused on developing external innovation strategies across therapeutic areas, and enabling the identification, diligence and establishment of external collaborations around emerging science, targets, technologies and preclinical assets. He was also responsible for the leadership of AbbVie China R&D Center in Shanghai, since its inception in 2009 and subsequently led the Renal Discovery Therapeutic Area, with responsibility for advancing programs in Chicago & Shanghai. Since 2015, he has taken on a leadership position within AbbVie’s Search & Evaluation team, with responsibilities for accessing and advancing opportunities in the Neuroscience Therapeutic area.

Murali obtained his undergraduate training in pharmacy from Banaras Hindu University, India and PhD in pharmacology from the School of Pharmacy, SUNY at Buffalo, New York. He completed his post-doctoral training in molecular biology at the Baylor College of Medicine, Houston, and has an MBA degree from the Lake Forest Graduate School of Management.
Speakers

Nessan Bermingham, CEO, Intellia Therapeutics, Inc.

Nessan Bermingham is the entrepreneur and Life Sciences investor whose vision and drive made Intellia “one of the top 10 biotech start-ups in 2014" according to Nature Biotechnology.

Nessan has more than 15 years of experience in Life Sciences investments, including small molecules, biologics, medical devices, and diagnostics through venture, public, and secondary markets. As a partner at Atlas Venture and Omega Funds, and founding partner of Bio Equity Capital, he successfully managed multiple investments across the United States and Europe. In his career, Nessan co-founded a number of healthcare and biotech startup companies. Most recently Nessan was a venture partner at Atlas Venture and was previously the CEO of Tal Medical, a medical device company spun out of Harvard Medical School. Nessan has established a vast transatlantic network of experts, management leaders, investors and companies that Intellia can leverage as it continues to grow.

Nessan serves on Intellia’s Board of Directors. He received his Ph.D. in Molecular Biology from Imperial College London and was a Howard Hughes Associate Fellow at Baylor College of Medicine.

Paul Thibodeau, Senior Director, Business Development, Teva Pharmaceutical Industries Ltd.

Paul Thibodeau has been with Teva Pharmaceuticals since 2013 and is currently Senior Director, Global Business Development where he focuses on transactions for Specialty Medicines. He is based in Boston, MA and responsible for transactions including licensing, product acquisitions, divestitures and out-licensing. Paul has held various roles in the biotech and pharmaceutical industry as well as in public policy. He started his career in business development at Genzyme where he supported the diagnostic, rare disease and oncology franchises. This was followed with a role in Sanofi’s corporate licensing group with responsibilities for licensing activities in oncology and for setting up its partnering strategy and approach for companion diagnostics. Prior to his experience in industry, Paul was a policy analyst at Health Canada and the Department of Foreign Affairs of the Government of Canada, and completed post-doctoral research at INSENM’s Hospital Bichat in Paris.

Paul has a Ph.D. in cell biology from the Universite de Sherbrooke and a MBA from the MIT Sloan School of Management.

Peter Thompson, Venture Partner, OrbiMed Advisors, LLC

Peter Thompson, M.D., is currently a Private Equity Partner with OrbiMed who brings over 20 years of industry experience. He co-founded and was CEO of Trubion Pharmaceuticals (NASDAQ: TRBN), co-founded Cleave BioSciences, is an executive of Chiron Corporation and Becton Dickinson and serves as a Director on several public and private company Boards. Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an Affiliate Professor of Neurosurgery at the University of Washington, an inventor on numerous patents, and a board-certified internist and oncologist. He was on staff at the National Cancer Institute following his internal medicine training at Yale University.
Speakers

PJ Anand, CEO, Alcyone Lifesciences, Inc.

PJ Anand is the founder of Alcyone Lifesciences, a company focused on novel treatment modalities for chronic neuropathological conditions and serves as its President and CEO with over 25 years of experience in the life science industry. PJ Anand also is a cofounder and Executive Chairman of Arthromeda, Inc., a company focused on orthopedic medicine & precision surgery. PJ Anand is a recognized expert in translating academic research into clinical value-proposition and in the area of convergence. Prior to founding Alcyone Lifesciences and Arthromeda, PJ Anand was a founding executive member of Arsenal Medical (now Arsenal Medical, Arsenal AAA, LLC and 480 Biomedical).

As Executive Vice President of Corporate Development, PJ Anand was responsible for leading Arsenal’s corporate strategy and business development activities including technology in-licensing, out-licensing and strategic alliances. In preparation for this role, PJ Anand served as the Company’s Vice President of Business and Commercial Development and working closely with Arsenal’s technology visionaries, operational team and founding scientists played a critical role in creation of Arsenal’s & 480’s platform and product portfolio as well as executing on key strategic alliance transactions.

Prior to joining Arsenal in 2005, PJ Anand served as Vice President & General Manager of Spire Biomedical, Inc., a division of Spire Corporation (NASDAQ: SPIR) where he was responsible for establishing a medical products business unit. While at Spire, PJ was responsible for R&D, sales & marketing and business transactions. In addition, PJ Anand was chiefly responsible for identifying and in-licensing the seminal technology for the company as well as executing major transactions with medical device companies that resulted in several million dollars of non-dilutive revenue for the company. PJ Anand has also served as head of business development for Toxikon Corporation, a preclinical CRO based out of Massachusetts.

PJ Anand has several patented & patent pending inventions and scientific publications to his credit.

Reinhard Gabathuler, Chief Scientist, bioOasis Technologies, Inc.

Dr. Gabathuler obtained his PhD in Plant Biochemistry at the Université de Lausanne, Switzerland, in 1982, and completed postdoctoral studies at the University of Washington, Seattle. Over the years, he has held various research positions including at the Swiss Institute for Experimental Cancer Research, Lausanne, the Ludwig Institute for Cancer Research at the Karolinska Institutet, Stockholm, Sweden; and the Biotechnology Laboratory of the University of British Columbia, Vancouver, Canada.

His research on a new vector for delivery of therapeutics to the brain led to the creation of Synapse Technologies Inc., where he became the Vice President of Research. The company was later acquired by BioMarin Pharmaceutical Inc., where Dr. Gabathuler assumed the position of Vice President of Brain Research.

Dr. Gabathuler joined AngioChem Inc. in 2004 as its Chief Scientific Officer, where he applied his extensive knowledge in biochemistry, cell biology, and immunology to directing the R&D programs, advancing the company’s product ANG1005 to IND application and the clinic.

Dr. Gabathuler is now working as Chief Scientist at bioOasis Technologies Inc., developing a new platform technology called Transcend for the delivery of a variety of therapeutic drugs to the brain. He is also the President and CEO of bioMmune Technologies Inc., concerned with the discovery and development of new therapeutics to restore immuno-recognition of tumor cells and to modulation of the activity of the immune system.

Robert Silverman, Head External Drug Discovery Partnering, Roche

Bob Silverman leads the “External Drug Discovery Partnering” team of Roche Partnering. Among other matters, Bob is responsible for delivering a structured and systematic approach to venture capital that translates to reach into drug discovery stage innovation via deals originating from venture capital interactions. Prior to his current role, from 2010 – 2012 Bob was a project leader for Merger & Acquisitions, in the Strategic Partnering Group of Roche Partnering. From 2003 – 2010 Bob was a Global Licensing Director for Roche Pharma Partnering, responsible for negotiating intellectual property based licensing agreements across the full value chain of the Pharma business, ranging from enabling technologies and early phase opportunities to clinical stage assets to promoting and divesting marketed products. From 2001 – 2003 Bob was a Global Licensing Attorney. Bob joined Roche in 1993. Early in his career at Roche Bob was Senior Counsel for the US Affiliate patent department. Bob holds a degree in Chemistry from Franklin & Marshall College and a J.D. from Boston University School of Law, and is a registered patent attorney.
Ronald Notvest, **SVP Commercial Planning and Development, Tonix Pharmaceuticals Holding Corp.**

Dr. Ronald Notvest has focused his career on advancing drug development pipelines, having played key roles in the discovery, development, and commercialization of new therapeutics. Dr. Notvest joined Tonix Pharmaceuticals as Senior Vice-President, Commercial Planning and Development in June, 2014.

He began his career with Ayerst Research heading up a drug discovery program for novel glutamate antagonists, while also being involved in the pharmacological characterization of potential drugs for Alzheimer’s and diabetic neuropathy. Subsequently, Dr. Notvest had the responsibility of providing early commercial input and guidance for a portfolio of over twenty early to late-stage development assets at Wyeth Pharmaceuticals. He served as commercial team leader for several products that advanced into late-stage development, and as one of his leads progressed, he transitioned into brand management and successfully launched and marketed a new immunosuppressant to prevent organ rejection after transplantation. In 2002, Dr. Notvest founded Evident, a consultancy that focused on commercial and financial assessments, as well as creating marketing and commercialization plans for drug candidates being developed by small and mid-size pharmaceutical companies. While at Evident, he consulted for Tonix, before joining full-time in 2014.

---

Ryan Westphal, **Sr. Director, Neuroscience Search & Evaluation, Eli Lilly and Co.**

Ryan Westphal has a B.Sc. in Pharmacy from South Dakota State University and a Ph.D. in Pharmacology from Vanderbilt University. Following post-doctoral fellowships at Vanderbilt and The Vollum Institute, in 2000 Ryan joined the Neuroscience Discovery group at Bristol-Myers Squibb leading the Molecular Pharmacology and Lead Evaluation teams. During his time at BMS, Ryan was responsible for leading discovery programs in psychiatry, pain, and neurodegenerative diseases and led discovery alliances with Lexicon Pharmaceuticals and Vanderbilt University. In 2013 Ryan went to FORUM Pharmaceuticals as Director Search & Evaluation identifying licensing opportunities in neuroscience and building the company’s competitive intelligence function. In 2014 Ryan accepted a position as Sr. Director Neuroscience Search & Evaluation at Eli Lilly responsible for identification and evaluation of licensing opportunities for Lilly Research Labs and the Biomedicines Business Unit across all phases of development. Ryan is also responsible for developing Lilly’s regional neuroscience interactions at key academic hubs of scientific excellence across the U.S. A key part of this role is expanding Lilly’s Neuroscience interactions within New York City including academics, venture funds, foundations, and biotech companies.

---

Stacie Weninger, **Executive Director, F-Prime Biomedical Research Initiative**

Stacie Weninger is the Executive Director of the F-Prime Biomedical Research Initiative. Prior to this position, she was the Senior Director of Science Programs for the Fidelity Foundations. In 2005, Dr. Weninger served as the Project Manager and Senior Analyst for the Task Force on Women in Science at Harvard University. From 2001-2005, Dr. Weninger was a Senior Scientist at Cell Press for the journal Neuron. Before joining Cell Press, Dr. Weninger was a postdoctoral research fellow at Children’s Hospital Boston and Harvard Medical School with Dr. Bruce Yankner. She was a Howard Hughes Medical Institute predoctoral fellow in the Program in Neuroscience at Harvard University. While a graduate student and postdoctoral research fellow, Dr. Weninger was actively involved in undergraduate teaching, winning six teaching awards.

Dr. Weninger received a Ph.D. in neuroscience from Harvard University, and a B.S. degree in chemistry with highest honors from the University of North Carolina, Chapel Hill. She currently chairs the Collaboration for Alzheimer’s Prevention; is President of Alzforum; serves as Chairman of the Board of Directors for Rogen Therapeutics; serves as a member of the Board of Directors for Denali Therapeutics, Zebra Medical Technologies, Aratome, Inscopix, BRI-Alzcan, BRI-Tolan, and Q-State Biosciences; and she previously served as a member of the Board of Directors for Annexon Biosciences.
Speakers

Stephen Webster, Chief Financial Officer, Spark Therapeutics, Inc.

Stephen Webster has over 25 years of experience serving as a financial professional in the life sciences industry. Prior to Spark, Stephen served as senior vice president, finance and chief financial officer at Optimer Pharmaceuticals, Inc., a commercial-stage company in the antibiotic field. Before that, he served in the same capacity at Adolor Corporation, a commercial-stage company in the gastro-intestinal space. Stephen played an integral role in the sale of both Optimer and Addolor to Cubist Pharmaceuticals, Inc. Prior to taking his first operating role, for 15 years Stephen was an investment banker to life sciences companies, raising over $3 billion in financings and advising clients on over $3 billion in aggregate mergers and acquisitions value. Stephen received his A.B. in economics, cum laude, from Dartmouth College and his M.B.A. in finance from the Wharton School at the University of Pennsylvania.

Steve Dickman, CEO, CBT Advisors

CBT Advisors Founder-CEO Steve Dickman has worked in the biotechnology and venture capital industries for more than fifteen years. He founded CBT Advisors in 2003 after completing a successful four-year stint as a venture capitalist with TVM Capital in Boston and Munich, where he invested in therapeutics, personalized medicine and life science research tools. His investments included Sirna Therapeutics, which was acquired in 2006 by Merck for $1.1 billion, and bluebird bio (then Genetix Pharmaceuticals), which went public on Nasdaq (BLUE) in 2013 and had a $3 billion valuation in December, 2015. Steve publishes from time to time on Forbes and Boston Biotech Watch.

CBT Advisors works in all areas of life sciences including drug discovery and clinical development, molecular diagnostics, genomics, research tools and bioinformatics and software. A growing area of focus is healthcare information technology (healthcare IT). CBT Advisors pursues projects of four basic types: • Drafting of prospectus text • Business development • Investor and partner pitches • Market analysis

Steven Perrin, CEO and CSO, ALS Therapy Development Inst.

Dr. Steven Perrin is currently the Chief Executive Officer and Chief Scientific Officer at the ALS Therapy Development Institute (ALS TDI) in Cambridge, MA. He earned his Ph.D. at Boston University Medical Center in the Department of Biochemistry. Steven moved into the pharmaceutical industry in 1997 holding positions at the Hoechst-Ariad, Genomics Center, Aventis Pharmaceuticals and more recently as Director of Molecular Profiling at Biogen Idec. Steven joined ALS TDI in 2007 as part of historical collaboration between the Muscular Dystrophy Association, Augie’s Quest and ALS TDI with the goal of developing a center of excellence for ALS drug development and translational research for neurodegenerative diseases.

Since joining ALS TDI Steven has spearheaded the architectural design and execution of the worlds largest Precision Medicine Program. This innovative program has bridged the gap between early preclinical target discovery and the advancement of biomarkers and quantitative outcome measures for clinical development in ALS and other neurological disease indications. Under his leadership ALS TDI has assembled a world class scientific team that in the last seven years has brought two potential treatments into clinical development for ALS. He has accomplished these objectives by creating innovative business models bridging philanthropic investments in early stages of drug development with for virtual for profit biotechnology companies to manage clinical translation. Steven is a frequent invited participant and speaker in international conferences on computational biology, genomics, drug development, and neurodegeneration.
Speakers

Thomas Heffner, Executive Director of Worldwide Business Development, Pfizer, Inc.

Tom Heffner is Executive Director, Worldwide Business Development, Pfizer Inc where he is responsible for Neuroscience. He joined Pfizer Business Development in 2005 and has been involved in licensing deals, co-promotion partnerships and acquisitions with a variety of companies. Prior to his current role, Tom was Vice President of Discovery Research at Pfizer Nagoya, Japan and there led research in Neuroscience and Pain. Before this, he led the Parke-Davis USA Neuroscience Discovery Research as well as the Parke-Davis Cambridge UK Neuroscience Research Centre and co-led Pfizer Global Neuroscience Discovery Research following the acquisition of Parke-Davis/Warner-Lambert by Pfizer. Tom has represented Pfizer on the Board of the New York Pharma Forum since 2005 and is currently President of that organization.

After receiving a Ph.D. in Biology from the University of Pittsburgh, Tom joined the faculty of the Department of Pharmacological & Physiological Sciences of the University of Chicago where he led NIMH-funded research on the central nervous system actions of psychostimulant drugs and the biological basis of Attentional Deficit Hyperactivity Disorder as well taught psychopharmacology in the Pritzker School of Medicine. Tom joined Parke-Davis in 1983 where he led Research and Development teams in psychiatric and neurological therapeutics. His groups in Ann Arbor and Cambridge were responsible for the discovery of Lyrica®. He is an author on over 100 scientific publications and is a former member of the editorial boards of Psychopharmacology and The Journal of Pharmacology and Experimental Therapeutics.

Timo Veromaa, President and CEO, Biotie Therapies Corp.

Timo Veromaa, M.D., Ph.D. is President and CEO of Biotie Therapies. Previously, he was Vice President, R&D at Biotie from 1998-2005, Medical Director at Schering AG (Finland) from 1996-1998, Program Director at Collagen Corporation (California, USA) from 1994-1996 and Postdoc Fellow at Stanford University (California, USA), from 1990-1993. He is Chairman of the Board of Finnish Bioindustries, Member of the Board of Directors of the Chemical Industry Federation of Finland and a Member of the Board of Directors of Herantis Pharma Ltd.

Todd Sherer, Chief Executive Officer, Michael J. Fox Foundation

Todd Sherer, PhD, is the Chief Executive Officer of The Michael J. Fox Foundation for Parkinson’s Research (MJFF), reporting to the Board of Directors. Formally trained as a neuroscientist, he directs the organization’s research strategy and is responsible for the organization’s overall scientific and fundraising direction to speed treatment breakthroughs and a cure for Parkinson’s disease.

Dr. Sherer has been a key architect of the Foundation’s strategy to define high-priority research areas for Parkinson’s disease - therapeutic targets and approaches that are closest or most critical to practical relevance in patients’ daily lives - in order to leverage donor-raised capital to push projects in these areas toward the clinic. He has played a major role in the Foundation’s efforts to increase the pharmaceutical industry’s investment in Parkinson’s disease drug development and engage the patient community to encourage and expand participation in clinical research. Today he is one of the world’s foremost experts on the science and business of Parkinson’s drug development, speaking frequently on these topics at conferences, to the media and to members of the Parkinson’s community.

Dr. Sherer’s work with the Foundation began in 2003, when, as a postdoctoral fellow at Emory University in Atlanta, he was awarded MJFF funding to investigate the role of environmental factors in Parkinson’s disease. He joined the Foundation’s staff full time as Associate Director, Research Programs, in April 2004. He was promoted to Vice President, Research Programs, in June 2006 and Chief Program Officer in November 2010, finally assuming the role of Chief Executive Officer in May 2011.

Dr. Sherer is a member of the Board of Directors of the Parkinson’s Action Network and participates in the Institute of Medicine of the National Academies Forum on Neuroscience and Nervous System Disorders. He is a collaborating scientist for the Coalition Against Major Diseases (CAMD) and a member of the CINAPS Advisory Committee at the National Institute for Neurodegenerative Disease and Stroke, National Institutes of Health (NIH). Dr. Sherer also serves on the National Center for Advancing Translational Sciences (NCATS) Council and the Cures Acceleration Network Review Board at the NIH. Additionally, Dr. Sherer was selected to serve as a council member on FasterCures’ TRAIN (The Research Acceleration and Innovation Network) program.

During his career as a bench researcher, Dr. Sherer published over 30 peer-reviewed articles in scientific journals. He earned his PhD in Neuroscience from the University of Virginia and holds a BS in Psychology from Duke University in Durham, North Carolina.
Vivek Ramaswamy, CEO, Axovant Sciences, Inc.

Vivek Ramaswamy is the founder of Roivant Sciences, a biopharmaceutical firm focused on the acquisition, development and commercialization of nonstrategic, deprioritized, or under-resourced drug candidates in areas of high unmet medical need, and of Axovant Sciences, a leading clinical-stage biopharmaceutical company dedicated to comprehensively addressing the cognitive, behavioral, and functional components of dementia. Mr. Ramaswamy serves as Chief Executive Officer of Roivant Sciences, Inc. and Axovant Sciences, Inc. He also serves as chairman of the board of directors of Arbutus Biopharma (formerly Tekmira Pharmaceuticals), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV).

Mr. Ramaswamy was previously a partner at QVT Financial LP, a global multi-strategy investment firm, where he was among the most widely respected healthcare investors with a strong track record of biotechnology investments. He also has prior experience as a successful entrepreneur in the technology industry. Mr. Ramaswamy holds an A.B. in biology, summa cum laude, from Harvard College and J.D. from Yale Law School.
1st ANNUAL  
Neuroscience BioPartnering & Investment Forum

AgeneBio, Inc.  
www.agenebio.com

CONTACT  
Jerry McLaughlin  
President and CEO

ADDRESS  
1101 E. 33rd Street, Suite C310  
Baltimore, MD 21218

TELEPHONE  
+1 443 451 7130

EMAIL  
investorrelations@agenebio.com

YEAR FOUNDED  
2008

SECTORS  
• Biotechnology • Pharmaceuticals/Licensing

FINANCIAL SUMMARY  
$18.5 million raised in equity and grants  
$2.6 million cash balance as of 12/31/15

COMPANY PROFILE  
AgeneBio, Inc., is a development-stage CNS biopharmaceutical company developing innovative therapeutics  
aimed at preserving and restoring brain function for unserved patients afflicted with neurological and psychiatric  
diseases. AgeneBio’s novel pipeline of therapies is based on decades of research at Johns Hopkins University  
and leading research centers worldwide showing that overactivity in the hippocampus contributes to cognitive  
impairment and drives neurodegeneration if not controlled. This overactivity is a characteristic feature of  
amnestic mild cognitive impairment (aMCI), the symptomatic pre-dementia stage of Alzheimer’s disease. If  
approved, AgeneBio’s Phase 3-ready lead candidate AGB101 will be the first and only therapeutic targeting  
hippocampal overactivity and potentially the first therapeutic to slow progression to and delay the onset of  
AgeneBio also has a novel GABA-A alpha5 small molecule program in late discovery stage with therapeutic  
potential for a spectrum of untreated conditions including aMCI, autism and schizophrenia.

PIPELINE

<table>
<thead>
<tr>
<th>AgeneBio Pipeline</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGB101</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discovery: GABA_A alpha5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase 3: HOPE4MCI</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IND Filed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase 2a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AGB101/Phase 3  
AgeneBio’s lead candidate, AGB101, is the first and only therapeutic targeting brain network imbalance for  
a large unserved patient population with aMCI due to Alzheimer’s disease (or prodromal AD), the earliest  
symptomatic stage characterized by memory loss.

AGB101 is a proprietary once-a-day low-dose formulation of levetiracetam, an anti-epileptic treatment  
commercialized for more than a decade with a well-characterized safety profile at daily doses greater than  
twelve times the intended dose for AGB101. Phase 2 clinical results showed that AGB101 restored brain  
network function and significantly improved memory in elderly patients with aMCI. AgeneBio expects to initiate  
the HOPE4MCI Phase 3 trial in 2016 using a primary endpoint that is aligned with recent US Food and Drug  
Administration (FDA) guidance for aMCI trials. If approved, AGB101 would be the first and only therapeutic  
that reduces hippocampal overactivity and potentially the first therapeutic to prevent or delay the onset of  
Alzheimer’s dementia. The trial is supported in part by a grant from the National Institutes of Health’s (NIH’s)  
National Institute on Aging (NIA) through a public-private partnership of the NIA, AgeneBio and Johns Hopkins  
University. Co-principal investigators on the NIH grant are Michela Gallagher, PhD, Krieger-Eisenhower Professor  
of Psychological and Brain Sciences and Director of the Neurogenetics and Behavior Center at Johns Hopkins  
University and AgeneBio founder, and Marilyn Albert, PhD, Professor of Neurology and Director of the Division
...continued

of Cognitive Neuroscience in the Department of Neurology at Johns Hopkins University School of Medicine and Director of the Johns Hopkins Alzheimer’s Disease Research Center (JHADRC).

**GABAA 5 positive allosteric modulators/development**
AgeneBio has a novel GABAA 5 small molecule program in late discovery stage with potential to address unmet needs for several diseases of the central nervous system including aMCI, autism and schizophrenia.

Our GABAA 5 Positive Allosteric Modulator (PAM) program builds on the science developed for the AGB101 program. With a high density of GABAA 5 receptors in the hippocampus, compounds that act as GABAA 5 PAMs are well positioned to attenuate and control hippocampal overactivity. Proof of biology studies demonstrate that GABAA 5 PAMs from multiple structural classes occupy GABAA 5 receptors in the hippocampus and improve memory impairment in aged animals.

The technology and patents behind AgeneBio’s early-stage program were discovered and initially developed by researchers at Johns Hopkins University, including the company’s founder and chief scientific officer, Michela Gallagher, PhD. We expect to submit our IND for this development asset in 2016.

**OPPORTUNITY**
Potential Partnerships and Financing
Contemplating partnerships and financing.

**MANAGEMENT**
Jerry McLaughlin, CEO & President, BOD
25-year commercial veteran of the pharmaceutical industry: Merck, Endo, NuPathe
Michela Gallagher, Ph.D., Founder & Scientific Advisor, BOD
20 years researching the neurobiology of aging: Johns Hopkins University, UNC-Chapel Hill
Sharon Rosenzweig-Lipson, Ph.D., VP of R&D
>20 years developing compounds for neurologic indications: Pfizer, Wyeth, AHP
Richard C. Mohs, Ph.D., VP of Clinical Dev.
>30 years in clinical development: Eli Lilly, Mount Sinai; Led Eli Lilly’s Phase 3 development team for Alzheimer’s candidates solenazumab and semagacestat
Steven Mulcahy, M.S, Director, Clinical Ops
>20 years managing clinical trials: Consolidated Clinical Trials, INC Research, U of Pitt Cancer Institute, Cephalon
SECTOR
• Biotechnology

COMPANY PROFILE
We are a publicly traded, emerging pharmaceutical company primarily focused on the development and commercialization of our proprietary drug, METADOXINE EXTENDED RELEASE (MDX), to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome (FXS).

MDX is not a stimulant; it works through a different mechanism of action than other ADHD treatments. Alcobra has completed multiple Phase II studies of MDX in adults and adolescents with ADHD and FXS and a Phase III study of MDX in adults with ADHD. The company is currently conducting a second, pivotal Phase III trial of MDX in adult ADHD.

PRODUCT PIPELINE
MDX for Adult ADHD
Attention-deficit/hyperactivity disorder (ADHD) is a common and impairing neuropsychiatric condition. Once believed to only affect children, ADHD is now known to persist into adolescence and adulthood in the majority of cases. Approximately 4-5% of adults worldwide are affected with ADHD.

Most adults with ADHD remain undiagnosed and untreated. While approved stimulant medications have been shown to be effective and safe for the treatment of ADHD, up to 30% to 50% of those who are prescribed stimulants for ADHD either do not respond to or do not tolerate these treatments; the utility of stimulants is further hindered by potential risk for abuse (stimulants are controlled substances regulated by the DEA and other international government agencies). Consequently, it is important to develop safe and effective non-stimulant treatment alternatives.

METADOXINE EXTENDED RELEASE (MDX) is an extended-release oral formulation of metadoxine (pyridoxol L-2-pyrrolidone-5-carboxylate). Metadoxine displays high affinity to the GABA transporter, while it does not bind to any other monoamine transporters (dopamine, serotonin, or norepinephrine) and does not affect dopamine, norepinephrine, and serotonin levels. Metadoxine is also an inhibitor of the GABA transaminase enzyme, which is responsible for the degradation of GABA. Electrophysiological studies showed that Metadoxine caused a dose-dependent, reversible reduction in glutamatergic excitatory transmission and enhancement of GABAergic inhibitory transmission, changes that may be associated with cognitive regulation. Alcobra has completed two Phase II, placebo controlled double blind studies in adults with ADHD. The first trial was completed in 2011, and was a six-week randomized, double-blind, placebo-controlled, parallel-group, multi-center Phase IIb study in 120 adult subjects with ADHD. Results of this study were published in the December 2012 issue of the Journal of Clinical Psychiatry (click to view) and the July 2013 issue of Postgraduate Medicine (click to view). The second trial was completed in 2013 and was a randomized, double-blind, placebo-controlled, cross-over single center study that enrolled 36 adult subjects with Primarily Inattentive ADHD. Results from this study were announced in a press release in December 2013 (click to view). Alcobra has completed one Phase III study in 300 adult subjects with ADHD. Results of this study were reported at the October 2014 American Academy of Child and Adolescent Psychiatry annual meeting (click to view). Alcobra is currently conducting a second, pivotal phase III study of MDX in adults with ADHD.

MDX for Paediatric ADHD
Attention-deficit/hyperactivity disorder (ADHD) is the most common neurobehavioral disorder of childhood. According to the US Centers for Disease Control and Prevention (CDC) National Health & Nutrition survey (NHANES), about 9% of children in the US meet criteria for ADHD with similar numbers reported in other countries. Although boys are more commonly diagnosed, ADHD is also common in girls, who often go undiagnosed.

Inattention, hyperactivity, and impulsivity are the key behaviors of ADHD. It is normal for all children to be inattentive, hyperactive, or impulsive sometimes, but for children with ADHD, these behaviors are more severe and occur more often. To be diagnosed with the disorder, a child must have symptoms for 6 or more months...
...continued

to a degree that is greater than other children of the same age. These symptoms will interfere with the child’s function in two or more settings, such as home and school.

In most cases, ADHD is best treated with a combination of medication and behavior therapy. Good treatment plans will include close monitoring with follow-up office visits to provide any changes needed along the way. Research shows that behavioral therapy is an important part of treatment for children with ADHD. ADHD affects not only a child’s ability to pay attention or sit still at school, it also affects relationships with family and how well they do in their classes. Behavioral therapy is a treatment option that can help reduce these problems for children and should be started as soon as a diagnosis is made.

Medications can affect children differently, where one child may respond well to one medication, but not another. When determining the best treatment, the doctor might try different medications and doses, so it is important for parents to work with their child’s doctor to find the medication that works best for their child.

Alcobra has completed a safety and tolerability study of MDX in adolescents with ADHD. Preliminary results of this study were reported in early 2015 (click to view). Alcobra intends to further study MDX in children and adolescents with ADHD. Upon completion of these studies, Alcobra will seek approval from the FDA and other regulatory agencies for the use of MDX in these patients.

MDX for Fragile X
Fragile X Syndrome, a rare disease, is the most common single-gene cause of autism and inherited cause of intellectual disability among boys. Approximately one in 4,000 males and one in 8,000 females have Fragile X Syndrome, according to the US Centers for Disease Control and Prevention (CDC). Not everyone with the mutation will show signs or symptoms of Fragile X Syndrome, and disabilities will range from mild to severe and may include intellectual disability and behavioral characteristics such as stereotypic movements (e.g., hand-flapping), problems with attention and hyperactivity and social anxiety. A majority of individuals with Fragile X Syndrome will have either Autism Spectrum Disorder or autistic symptoms, and will have varying levels of cognitive impairment. The FDA has not approved any drugs specifically for the treatment of Fragile X Syndrome or its symptoms. Because of the lack of an approved treatment for Fragile X Syndrome, there is substantial unmet medical need.

Alcobra has completed two animal studies of Fragile X Syndrome. The first study included multiple behavioral assessments of 40 mice, comprising 20 Fragile X knock-out mice and 20 control mice that were treated with Metadoxine or a placebo. The results showed significant improvement in behavioral outcomes, including contextual fear conditioning (a test primarily evaluating memory and learning), social interaction, and Y-maze alternation (a test of learning and perseverance). The second study included behavioral assessments of young and old Fragile X knock-out mice and control mice. This study showed that Metadoxine treatment led to significant improvement in blood and brain biological markers (AKT and ERK), which may have a role in learning and memory. The study also demonstrated a reduction in the amount of immature neurons and abnormally increased protein levels.

The positive outcomes reported in these animal models, together with the cognitive benefits demonstrated in our trials in ADHD, warrant investigation in human clinical trials to evaluate the safety and efficacy of METADOXINE EXTENDED RELEASE for treatment of Fragile X Syndrome. Alcobra has completed a phase II study in adolescents and adults with Fragile X Syndrome. Preliminary results from this study showing a signal of benefit on adaptive behavior in FXS were reported by Alcobra in June 2015.

MANAGEMENT
Yaron Daniely PhD MBA CEO
Dr. Yaron Daniely became our President and Chief Executive Officer and a Director in March 2010. Immediately prior to joining us and since 2007, Dr. Daniely was the President and Chief Executive Officer of NanoCyte, Inc., a company that develops transdermal delivery technologies for the pharmaceutical and cosmetic industry based in Caesarea, Israel. Before NanoCyte and from 2004, Dr. Daniely was the General Manager of Gamida Cell—Teva Joint Venture Ltd., a Phase III-stage cell therapy joint venture focused on the treatment of Leukemia and Lymphoma. From 2003-2007, Dr. Daniely also served as the Vice...continued...
President of Business Development of Gamida Cell Ltd., and engaged in several licensing and financial transactions for the Company. Dr. Daniely holds a Ph.D. from New York University School of Medicine. Following his doctoral program, Dr. Daniely served as a Visiting Fellow at NIH, and an American Cancer Society Postdoctoral Fellow at The Weizmann Institute for Science. Subsequently, he received an Executive M.B.A. from the Technion, Israel Institute of Technology. Dr. Daniely is also a faculty member in the Strategy and Entrepreneurship department of the College of Management in Israel, and heads the BIO-MBA academic program at the college.

**Tomer Berkovitz PhD, CFO**

Dr. Tomer Berkovitz joined Alcobra in May of 2014 as the Chief Financial Officer. Prior to joining Alcobra, he was an Executive Director in J.P. Morgan’s Investment Banking Division in New York, where he played a leading role in numerous capital markets and M&A transactions. In this capacity, he advised senior management and boards of directors of J.P. Morgan’s key U.S. clients, including several S&P 500 healthcare firms. Prior to joining J.P. Morgan, Dr. Berkovitz worked in Citigroup’s Investment Bank in New York. From 2000 to 2003, he served as an Economist in the Financial Advisory Unit to the Chief of Staff of the Israel Defense Forces. Dr. Berkovitz holds a Ph.D. in Finance and Economics from Columbia Business School and has published a number of corporate finance articles in leading academic and practitioner journals. He also holds an M.Sc. in Finance and Accounting and a B.A. in Economics and Management, both from Tel-Aviv University.

**Jonathan Rubin MD MBA, CMO**

Dr. Jonathan Rubin joined Alcobra in August of 2013 as the Chief Medical Officer. Previously Dr. Rubin worked at Shire Development for over six years serving as Medical Director in Global Medical Affairs supporting multiple products within the ADHD portfolio. As a Medical Director in Global Medical Affairs at Shire, Dr. Rubin developed and implemented Global Medical Affairs strategic plans, planned and supervised medical launch activities in the United States, and assisted with the design, execution and interpretation of Phase II, III and Phase IV studies. Dr. Rubin also served as the Director of Scientific Licensing Assessment at Shire from March to December 2011 where he identified and evaluated new opportunities for business development. Dr. Rubin began his pharmaceutical industry career as a medical consultant for Noven Pharmaceuticals in 2002. He cared for children and adolescents with ADHD for 15 years at his General and Developmental-Behavioral Pediatric practice in Margate and Coconut Creek, Florida.

He graduated with a BS from Yale University, an MD from the University of Connecticut, completed a Pediatric Residency at Albert Einstein/Montefiore, completed an Ambulatory Pediatric fellowship at Boston Children’s Hospital and received an MBA from Columbia Business School.

**David Baker, CCO**

Mr. Baker joined Alcobra in January 2014 as the Chief Commercial Officer. Prior to joining Alcobra, he worked at Shire for 10 years, most recently as Vice President of Commercial Strategy and New Business in the Neuroscience Business Unit. In that role, he led the commercial assessment of neuroscience licensing opportunities, managed commercial efforts on pipeline CNS products, and led the long term strategic planning process. Previously, he served as Global General Manager for Vyvanse® where he led the launch of Vyvanse, led the launch of the adult indication for Vyvanse, and led global expansion efforts including successful establishment of a partnership in Japan and launches in Canada and Brazil. Prior to that, Mr. Baker served as Vice President of Marketing for all of Shire’s ADHD products. He has been directly involved with the commercialization of five approved ADHD medications.

From 1990 - 2004, Mr. Baker worked at Merck where he held positions of increasing responsibility in marketing, sales, market research, and business development. In addition to his knowledge and experience with CNS medications, Mr. Baker’s therapeutic expertise includes osteoporosis, migraine, and hyperlipidemia. He has been directly involved with the marketing of five medications with annual sales in excess of $1 billion each.

Mr. Baker graduated Magna Cum Laude with a bachelor’s degree in Economics and Computer Science from Duke University. He earned a Master of Business Administration in Marketing from Duke’s Fuqua School of Business.
1st ANNUAL
Neuroscience BioPartnering & Investment Forum

Alcyone Lifesciences, Inc.
www.alcyonels.com

CONTACT
PJ Anand
Founder, Chief Executive Officer

ADDRESS
250 Jackson Street
Unit 494 Mill No. 5 Building
Lowell, Massachusetts 01852, USA

TELEPHONE
+1 978 709 1946

EMAIL
info@alcyonels.com

YEAR FOUNDED
2010

SECTORS
• Biotechnology • Drug Delivery • Medical Devices

COMPANY PROFILE
Alcyone Lifesciences was founded in 2010 to address the unmet needs in treatment of chronic neuropathological conditions. For many neurologic conditions including brain tumor, hydrocephalus, epilepsy and neurodegenerative disease, the current treatment modalities are sub-optimal. Alcyone is dedicated to developing biologically inspired and clinically relevant solutions to significantly enhance current treatment modes for patients suffering from these chronic conditions.

MANAGEMENT
PJ Anand, Founder, Chief Executive Officer
Adam Fleisher, MD, MAS, Co-founder
Elsa Abruzzo, RAC, FRAPS., Vice President of Regulatory, Quality and Clinical Affairs
Deep Singh, Lead Project Engineer/Manager
Andrew East, Program Manager
Morgan Brophy, Project Engineer
COMPANY PROFILE

Amarantus BioScience Holdings, Inc. is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine, and diagnostics in neurology. The Company’s lead therapeutic program, eltoprazine, is a small molecule indicated for the treatment of Levodopa-induced dyskinesia, one of the most difficult problems facing patients with Parkinson’s disease. Eltoprazine is currently in a Phase 2b clinical trial with results from the study expected in 2016. Eltoprazine is also being evaluated for the treatment of adult attention deficit hyperactivity disorder (ADHD) and Alzheimer’s aggression.

PIPELINE

Therapeutic Pipeline: Dominated by Clinical Stage Assets

MANF Preclinical Pipeline Has Revolutionary Potential

Diagnostics Pipeline Ready for Strategic Transactions

MANAGEMENT

Gerald E. Commissiong, President & CEO
Robert Farrell, J.D., Chief Financial Officer
John W. Commissiong, Ph.D., Chief Scientific Officer
Elise Brownell, Ph.D., Senior Vice President of Operations and Project Management
Curtis Scribner, M.D., M.B.A., Senior Vice President of Regulatory Affairs
Marc E. Faerber, Corporate Controller and Vice President of Financial Operations
Anelixis Therapeutics

**COMPANY PROFILE**

Anelixis was formed in 2013 and is a for-profit subsidiary of ALS Therapy Development Institute (ALS TDI), a nonprofit biotechnology organization dedicated to developing effective treatments for ALS.

In recent years the economics of developing transformative new treatments for patients has become challenging for the pharmaceutical industry. In order to decrease the costly early stage of basic research and drug discovery/development, Anelixis Therapeutics will leverage over ten years of expertise in target validation and lead molecule optimization at ALS TDI. ALS TDI performs preclinical proof of concept studies with established in vitro and in vivo assay systems. Anelixis can license lead candidates generated at ALS TDI as well as to in license third party opportunities and validate these opportunities using ALS TDI’s established infrastructure.

Amyotrophic Lateral Sclerosis (ALS) is a progressive, fatal neurological disorder. It is an orphan disease with approximately 5,000 new cases diagnosed annually and a prevalence of 30,000 patients in the United States and 450,000 patients globally. Patients exhibit a median survival time of 3-5 years following diagnosis, during which time loss of motor neurons in the spinal cord results in progressive muscle atrophy, paralysis, and eventually respiratory failure due to atrophy of the diaphragm muscles. The economic burden on the US health care system to provide care to people living with ALS is $1.2B and increasing annually.

Early interventions with non-invasive respiratory assistance, insertion of percutaneous endoscopic gastrostomy feeding tubes, and advances in communication devices have resulted in improved quality of life for many people living with ALS. However, these interventions are only supportive: they do not inhibit progressive muscle atrophy, do not slow disease progression and do not improve survival.

The only FDA approved therapeutic drug for ALS is Riluzole (tradename Rilutek), a glutamate transport antagonist marketed by Sanofi Aventis. Riluzole has demonstrated neuroprotective properties in multiple neurological disease indications via modulation of voltage dependent sodium channel activity and inhibiting excitatory amino acid release. Several clinical trials in the US and Europe have demonstrated a therapeutic benefit of Riluzole in ALS, as measured by time to tracheotomy and survival. However, the therapeutic benefit of Riluzole is only about 10% (−90 days) due to limitations in its pharmacological properties, including biodistribution to the central nervous system (CNS), active transport out of the CNS, and effects on other sodium channels.

Studies presented have demonstrated the proof of concept for our strategy of blocking the CD40/CD40LG arm of the costimulatory pathway as a potentially therapeutic approach to ALS. Specifically, we have demonstrated that immune cells are activated and infiltrate the nervous tissue and neuromuscular junctions (NMJs) of ALS patients. By blocking the costimulatory pathway using an antibody against CD40LG reduces lymphocyte activation, accumulation of macrophages in NMJs, and delays key components of ALS pathology in the SOD1G93A murine ALS model, including longer latency to disease onset and prolonged survival, in a dose dependent manner. The clinical candidate (AT-1501) which developed at ALS TDI is based on the humanized anti-CD40LG antibody 5c8 and the Abatacept Fc domain, which does not bind Fc receptors and does not cause platelet aggregation. This antibody binds CD40LG with high affinity and does not induce platelet aggregation, suggesting that it is not likely to be tainted with the safety concerns associated with previous anti-CD40LG therapy.

**MANAGEMENT**

**Steven Perrin, Ph.D., CEO**

Dr. Perrin has held positions in several pharmaceutical and joined ALS TDI in 2007 to develop and manage a scientific and business strategy to bring effective treatments to the clinic for ALS patients. He has fostered business development relationships with a dozen biotech and pharmaceutical companies in the ALS field and created a novel business model bridging the non profit research.

**Augie Nieto, Chairman**

A pioneer in the fitness industry, Augie co-founded Life Fitness, a manufacturer of cardiovascular and strength training fitness equipment, in 1980. Over the course of 20 years, he grew the company to be the largest commercial manufacturer of fitness equipment in the world. In 2005, Augie was diagnosed with amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease). Augie along with his wife, Lynne, founded the Augie’s Quest initiative in 2006. He currently serves as chairman of Octane Fitness, is on the board of Curves & Jenny Craig, and is the Chairman of the Board at the ALS Therapy Development Institute.

**Pamela Hay Ph.D., Business Development**

Dr. Hay has more than 25 years of business development and legal experience working in private and public biotechnology companies. She is a partner at Red Sky Partners, a business advisory firm to the health care industry that provides strategy and transaction advice and interim management services to private and public biotech and biopharma companies.

**Peter Rock, CFO**

Peter Rock has held various financial positions in manufacturing, technology and biotech companies. He has been an independent contract CFO for early stage technology companies for the past 13 years. He received a B.B.A. from the University of Massachusetts, Amherst, and holds an M.B.A. from Rensselaer Polytechnic Institute.
biOasis Technologies, Inc.
www.bioasis.ca

SECTOR
- Biotechnology

FINANCIAL SUMMARY
Total shares outstanding: 45,379,257
Total diluted: 50,849,257
Market Cap (Feb 12/16): $49.46M

COMPANY PROFILE
biOasis Technologies Inc. is a ground-breaking biopharmaceutical company focused on the delivery of therapeutics across the blood-brain barrier and into the brain tissue. The delivery of therapeutics across the blood-brain barrier represents the single greatest challenge in the treatment of over a thousand common and rare diseases of the central nervous system.

biOasis is seeking to address these unmet medical needs with its proprietary Transcend Platform. Designed to transport therapeutics of varying types and sizes across the blood-brain barrier, the Transcend Platform is based on Receptor Mediated Transcytosis, nature’s own method of carrying compounds into the brain.

Located in Vancouver, Canada, biOasis is a publicly-traded company on the OTCQB under the symbol BIOAF and on the TSX Venture Exchange under BTI.

PIPPLELINE

<table>
<thead>
<tr>
<th>Objectives Achieved</th>
<th>Brain Transport</th>
<th>Quantity in the Brain</th>
<th>Localization in Brain (Cellular)</th>
<th>Efficacy Models</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doxorubicin: Gliomas</td>
<td></td>
<td>~77% increase in survival time</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paclitaxel: Tumours</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Herceptin: Breast Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cetuximab: Lung Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lysosomal Storage Disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hurlers Syndrome: MPS I Model</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hunters Syndrome: MPS II Model</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sandhoff Disease: Hex B Model</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stroke</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>siRNA (Nox4)</td>
<td></td>
<td></td>
<td></td>
<td>Reduced neurological deficiency</td>
</tr>
</tbody>
</table>

OPPORTUNITY

Transcend Program - Blood Brain Barrier Delivery Platform
biOasis’ Transcend Platform is a group of proprietary technologies designed for the transport of therapeutic agents across the blood brain barrier (“BBB”) and into the brain tissue. The delivery of therapeutics across the BBB represents the single greatest challenge in the treatment of over a thousand common and rare diseases of the brain and central nervous system. The development of an effective method to deliver therapeutics across the BBB has been considered for decades to be the “Holy Grail” of neurological medicine.

The technology is available for licensing in a wide range of CNS therapeutic areas.

MANAGEMENT
Mr. Rob Hutchison, CEO and Chairman
Dr. Wilfred Jefferies, Founding Scientist
Dr. Reinhard Gabathuler, Chief Scientist
Dr. Mei Mei Tian, Senior Scientist
Judi Dalling, CFO
Kim Elton, Director of Marketing
Willow Tree Capital Group, Business Development Advisors
CONTACT
John Kaiser
Chief Business Officer

ADDRESS
400 East Pratt Street, Suite 606
Baltimore, MD 21202

TELEPHONE
+1 410 522 8707

EMAIL
info@cerecor.com

YEAR FOUNDED
2011

SECTOR
• Biotechnology

COMPANY PROFILE
Cerecor is a biopharmaceutical company with the goal of becoming a leader in the development of innovative
drugs that make a difference in the lives of patients with neurological and psychiatric diseases. We are
committed to the development of drugs that improve lives by applying our extensive knowledge and experience
in central nervous system disorders. Cerecor is currently pursuing the development of two clinical Phase
II-stage product candidates: CERC-301: An oral, NR2B specific, NMDA receptor antagonist targeting the
adjunctive treatment of patients with MDD who are failing to achieve adequate response, and CERC-501. In
addition Cerecor is conducting preclinical testing of CERC-406, a brain penetrant COMT inhibitor with potential
procognitive activity.

PIPELINE

<table>
<thead>
<tr>
<th>Candidate</th>
<th>Mechanism</th>
<th>Potential Indication(s)</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERC-301</td>
<td>NR2B specific NMDA antagonist</td>
<td>Adjunctive treatment of MDD with a rapid onset</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CERC-501</td>
<td>Selective kappa opioid receptor (KOR) antagonist</td>
<td>Substance use disorders</td>
<td></td>
<td></td>
<td></td>
<td>Externally -sponsored studies</td>
</tr>
<tr>
<td>CERC-406</td>
<td>Selective, brain penetrant COMT inhibitor</td>
<td>Residual cognitive impairment symptoms in MDD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CERC-301 (Phase 2)
An oral, NR2B specific, NMDA antagonist for adjunctive treatment of major depressive disorder, with a rapid onset

CERC-501 (Phase 2)
A potent, selective kappa opioid receptor (KOR) antagonist being developed for substance use disorders; adjunctive treatment major depressive disorders (MDD)

CERC-406 (Preclinical)
Selective, brain penetrant COMT inhibitor in preclinical development for cognition and ADHD

MANAGEMENT
Uli Hacksell, Ph.D., CEO, President and Chairman
Ron Marcus, M.D., CMO and Head, Regulatory Affairs
John Kaiser, Chief Business Officer
Mariam Morris, Chief Financial Officer
Hether Fraser, Ph.D., VP, Clinical Operations and Project Mgmt
Cleveland Clinic & NeuroTherapia
www.neurotherapia.com

CONTACTS
Joseph Foss, M.D.
Mohamed Naguib Attala, M.D.

ADDRESS
Cleveland, Ohio

TELEPHONE
+1 216 870-7969

EMAIL
info@neurotherapia.com

YEAR FOUNDED
2007

SECTORS
• Biotechnology • Academia • Pharmaceuticals/Licensing

COMPANY PROFILE
We are in the preclinical stage developing a novel small molecule for the treatment of neuroinflammatory diseases including neuropathic pain, chemotherapy induced peripheral neuropathy and Alzheimer’s disease.

PRODUCT PIPELINE
NTRX-07 Preclinical
NTRX-07 is a NME small molecule which reduces neuroinflammation by acting on the microglia...

MANAGEMENT
Joseph Foss, M.D.
Mohamed Naguib Attala, M.D.
**Cognition Therapeutics, Inc.**

www.cogrx.com

---

**SECTOR**
- Biotechnology

**COMPANY PROFILE**

Cognition Therapeutics (CogRx) is a clinical-stage small molecule therapeutics company focused on the discovery and development of novel drugs for neurodegenerative diseases. Its Alzheimer’s disease program is comprised of a small molecule therapeutic that directly blocks the action of toxic soluble amyloid beta (Aß) oligomer proteins that cause the progressive memory loss, the primary and devastating hallmark of Alzheimer’s disease. Using its proprietary discovery platforms, CogRx has discovered first-in-class receptor antagonist compounds that selectively block these soluble Aß oligomers from causing cognitive decline. CogRx’s small molecule therapeutic works through the allosteric modulation of a key regulator of membrane trafficking, disrupting the neuronal Aß oligomer receptor complex and displacing bound Aß oligomers from synapses. These actions result in the reversal of memory loss in Alzheimer’s disease models and stabilization of synapses. Significant improvements in memory and slowing or halting of disease progression are anticipated.

**PRODUCT PIPELINE**

- Small molecule s2/PGRMC1 antagonist: Phase 1
  CogRx’s drug displaces bound oligomers from their receptors by allosterically modulating sigma 2/PGRMC1 protein, which in turn alters the conformation of a tightly associated oligomer receptor.

**MANAGEMENT**

- Dr. Susan Catalano, Founder and CSO
- Dr. Hank Safferstein, President and CEO
- Dr. Michael Grundman, CMO
- Dr. Gilbert Rishton, Chief Medicinal Chemist

---

**CONTACTS**

Dr. Susan Catalano
Founder and CSO

Dr. Hank Safferstein
President and CEO

**ADDRESS**

2403 Sidney St.
Suite 261
Pittsburgh PA, 15203

**TELEPHONE**

+1 412 481-2210

**EMAIL**

info@cogrx.com

**YEAR FOUNDED**

2007
Empriver

COMPANY PROFILE
Empriver has developed and patented an innovative approach to selectively target neurotoxic conformers of pathogenic proteins in neurodegenerative diseases. This selectivity will minimize the possibility of toxic side effects, which have hampered the field. We take advantage of a rare and unique strain of pathologic amyloid, with a non-self sequence. This allows us to pursue active and passive immunization strategies, where antibodies will recognize common motifs in amyloid associated with A-beta and tau, as well as a-synuclein and TDP43, to slow the progression of Alzheimer’s, Parkinson’s, ALS, and other debilitating neurological disorders.

Concurrently, we have also developed and patented an approach to induce the innate immune system, via activation of toll-like receptor 9, to clear pathogenic proteins in Alzheimer’s disease. With these unique therapeutic approaches, Empriver is positioned to address one of the most pressing health issues facing the world.
Heptares Therapeutics
www.heptares.com

CONTACT
Dr. Barry Kenny
CBO

ADDRESS
BioPark,
Broadwater Road,
Welwyn Garden City,
Hertfordshire,
AL7 3AX,
UK

TELEPHONE
+44 (0) 1707 358 628

EMAIL
info@heptares.com

SECTOR
• Biotechnology

COMPANY PROFILE
Heptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Our proprietary structure-based drug design platform has enabled us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, schizophrenia, migraine, addiction, metabolic disease, and other indications. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple partners including AstraZeneca, Morphosys, Pfizer and Teva.

Heptares is a wholly owned subsidiary of Sosei Group Corporation.

PIPELINE
(for full pipeline visit; http://www.heptares.com/pipeline/)

Selective Muscarinic M1 agonist for AD and other cognitive disorders in Phase 1 clinical development.
First-in-class selective muscarinic M1 receptor agonist in Phase 1b clinical development. Phase 2 studies are scheduled for 2016.

Selective Orexin-1 antagonist / Lead optimisation
First selective orexin OX1 receptor antagonist in preclinical development for the treatment of cocaine addiction and with potential broad applications in substance addictions (nicotine, alcohol) and compulsive disorders (binge eating, gambling). Highly potent and novel leads have been discovered using Heptares structural GPCR platform and are being advanced through to candidate selection.

mGlu5 NAM (negative allosteric modulator) / IND enabling studies
Novel mGlu5 NAM in late stage pre-clinical development with potential for the treatment of several CNS disorders including depression, LID and dystonia.

MANAGEMENT
Dr. Malcolm Weir, CEO
Dr. Fiona Marshall, CSO
Dr. Barry Kenny, CBO
Dr. Tim Tasker, CMO
Dr. Miles Congreve, VP, Chemistry
neurotecnix develops innovative neurotechnologies to diagnose and treat neurologic disorders. With patented technology @ Brown University and Rhode Island Hospital/Lifespan, neurotecnix recently developed a method to measure and quantify pain by decoding neuronal activity. This technology will disrupt major human and animal healthcare markets in which the gold standard for pain diagnosis remains largely subjective and suboptimal.

MANAGEMENT
Carl Saab, MS, Ph.D., Founder, CSO – Brown University, Rhode Island Hospital
Samer Saab, MBA, CFO – Int’l Monetary Fund, World Bank
Stephen Davis, Legal – Goodwin & Procter LLP, NY – Columbia University
Jason Naftulin, Business Development Intern – Brown University
Adam Nitenson, Business Development Intern – Brown University
Neurotrope BioScience
www.neurotropebioscience.com

SECTOR
- Biotechnology

FINANCIAL SUMMARY
Company has raised $39 million since formation. Company has over $10 million in cash.

COMPANY PROFILE
Neurotrope BioScience (OTCQB:NTRP), formed in 2012, is at the forefront of the biotech industry and is focused on developing new therapies with Bryostatin 1 for the treatment of neurodegenerative diseases and developmental disorders, primarily Alzheimer’s disease. The Company is currently enrolling patients in its Phase 2b clinical trial.

MANAGEMENT
Charles S. Ramat, President and CEO
Paul E. Freiman, Chairman of the Board
Dr. Dan Alkon, Chief Scientific Officer
Robert Weinstein, Chief Financial Officer
Oryzon Genomics SA
www.oryzon.com

SECTOR
- Biotechnology

FINANCIAL SUMMARY
A publicly traded company in the Madrid Stock Exchange since December 14th 2015.

MADX: ORY. Trading started at €3.39 = €96.5M Market Cap
A financing round in 2025 of 16.5M€
Strong balance sheet with €+20min cash
$5 million payment from ROCHE in 2015
Secured €2.6M in public aids in 2015
Unused credit line of €6 M from commercial banks
€10M in debt with low interest rates
- Repayment terms over either 3-4y or 8-10y (commercial loans or Public R&D loans)
- Rates from 0-3% (average cost of debt 1,3%)

Expected cash burn of €10-12M annually for next 2 years
Raised €31 M since inception
Spanish GAAP rules adapted to IFRS
Accounts audited by Grant Thornton since 2003 and through 2014
Audited in 1H 2015
35 employees

COMPANY PROFILE
Oryzon is a clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics.

With one compound in Phase I/IIA in oncology, ORY-1001, a highly potent LSD1 inhibitor with exquisite selectivity that has been granted orphan-drug status by the EMA, a second compound expected to enter in clinical development in 2016 for Alzheimer’s Disease and additional programs in other cancer indications, the company has a broad and growing portfolio.

Oryzon was founded in 2000 by Tamara Maes and Carlos Buesa. The company is headquartered in Barcelona, Spain with 30 employees, and is considered the biopharmaceutical company of reference in Spain.

From its founding through 2008, the company focused its efforts in growing a genomics diagnostics business model, providing genomics services to the pharmaceutical industry in Europe. In 2008, with the acquisition of Crystax Pharmaceuticals, we started our drug discovery programs in oncology and neurodegenerative diseases, with a focus on Alzheimer’s disease and hematological cancers. Our business model is to develop our proprietary drug candidates through clinical phase II.

The company has a seasoned executive management with vast experience in the industry.

Our lead oncology program was licensed in 2014 to Roche in a collaboration transaction valued at over $500 million.

PRODUCT PIPELINE
ORY2001. Phase I Alzheimer’s Disease
Ory-2001 can also be develop for orphan indications as Huntington Disease and Neuroinflammatory disorders
ORY-2001 is a highly selective dual LSD1-MAO-B inhibitor.
Preclinical Proof of Concept: LSD1 Against AD and HD.

Continued...
ORYZON

ORYZON Genomics SA
www.oryzon.com

…continued

ORY-2001
Clinical development Status: Ongoing Phase I in Healthy Volunteers
Alzheimer’s Disease is lead indication
Potential for additional indications: PD, HD and others

Excellent Pharmacological Properties
1. Optimal ADMET and PK profiles
2. Crosses efficiently the BBB
3. Once daily oral bioavailable
4. Good pharmaceutical properties
5. Selectivity against MAO-A demonstrated in-vitro and in-vivo
6. High therapeutic window in animals
7. Biomarkers identified for use in Clinical Trials

Exclusively owned by Oryzon.

MANAGEMENT
Dr. Carlos Buesa, Chief Executive Officer
Tamara Maes, Chief Scientific Officer
Enric Rello, Chief Operating Officer (COO), Chief Financial Officer in Spain
Neus Virgili, Chief Intellectual Property Officer
César Molinero, Chief Medical Officer
Emili Torrell, Chief Business Development Officer
Anna Baran, JD, Investor Relations Director

CONTACT
Dr. Carlos Buesa
Chief Executive Officer

ADDRESS
Sant Ferran 74
08940 Cornellà de Llobregat
Barcelona, SPAIN

TELEPHONE
+34 93 515 1313

EMAIL
info@oryzon.com

YEAR FOUNDED
2000

www.oryzon.com
Pharmasum Therapeutics AS
www.pharmasum.com

SECTORS
• Bioinformatics • Biotechnology

FINANCIAL SUMMARY
Raised NOK 20 million in share capital and non-dillutive grants
Looking to raise USD 10 m

COMPANY PROFILE
Pharmasum Therapeutics is a private, Norwegian pharmaceutical company focused on the discovery and development of novel human medicines for the treatment of brain diseases, especially neurological diseases.
The Company shall develop drugs to at least Proof-of-Concept stage, but will be seeking strategic partnerships with larger pharmaceutical companies potentially for early-stage collaborations, late-stage development and marketing. The preferred deal-structure takes form as a co-development partnership, where Pharmasum may reserve rights to marketing and co-promotion in certain territories. The Company shall also be open to non-organic growth through M&A processes.

PIPELINE

<table>
<thead>
<tr>
<th>PIPELINE</th>
<th>Target to hit</th>
<th>H2L</th>
<th>LO</th>
<th>IND-enabling</th>
</tr>
</thead>
<tbody>
<tr>
<td>PST-900</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DYRK1A</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delay of progression of dementia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PST-1000</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CK1d</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment of sleep disturbances in dementia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

DYRK1A inhibitor - treatment of dementia in Down syndrome. Lead Optimisation stage
CK1 inhibitor - treatment of sleep disturbance in Alzheimer’s disease

OPPORTUNITY
Series A
Looking to raise USD 10m Series A during 2016

MANAGEMENT
Anders Fugelli, Ph.D., Chief Executive Officer
John Sigurd Svendsen, Ph.D., Chief Scientific Officer
Pauline Stewart-Long, Ph.D., Head of Project Management
Henning Mork, MSc., CFO
Rick Engh, Ph.D., Advisor on Structural Biology
Andrew Parsons, Ph.D., Chairman of the Board
Oystein Soug, MSc., Non-exec Director
Masha Stromme, Ph.D., Non-exec Director
Probiodrug AG
www.probiodrug.de

SECTOR
• Biotechnology

COMPANY PROFILE
Probiodrug AG is a biopharmaceutical company dedicated to the research and development of new therapeutic products for the treatment of Alzheimer’s disease (“AD”).

Headquartered in Halle, Germany, Probiodrug was founded in 1997 by Prof Dr Hans-Ulrich Demuth and Dr Konrad Glund and successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors / gliptins. Today Probiodrug’s aim is to become a leading company in the development of Alzheimer’s treatments and to thereby provide a better life for patients.

Probiodrug has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight AD.

PRODUCT PIPELINE

<table>
<thead>
<tr>
<th>Product</th>
<th>Pre-clinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>PQ912</td>
<td>Small molecule QC inhibitor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PBD-C06</td>
<td>pGlu-Abeta specific monoclonal antibody</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PQ1565</td>
<td>Small molecule QC inhibitor</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PQ912, phase 2a
PBD-C06, preclinical
PQ1565, preclinical

MANAGEMENT
Konrad Glund, C00
Hendrik Liebers, CFO
Inge Lues, CDO
PsychoGenics, Inc.
www.psychogenics.com

CONTACT
Emer Leahy, Ph.D., President & CEO

ADDRESS
765 Old Saw Mill River Road
Tarrytown, NY 10591

TELEPHONE
+1 914-406-8019

EMAIL
info@psychogenics.com

YEAR FOUNDED
1999

SECTORS
• Biotechnology • CRO

COMPANY PROFILE
PsychoGenics is a leading provider of preclinical CNS services. The Company’s capabilities include behavioral testing, electrophysiology, translational EEG, quantitative histology, molecular biology, and microdialysis. Complementing its extensive capabilities, the company has a variety of mouse models including in-licensed transgenic models that support research in areas such as Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, Autism spectrum disorders, psychosis/schizophrenia, Spinal Muscular Atrophy (SMA), muscular dystrophy and other muscle disorders. PsychoGenics has also pioneered the translation of rodent behavioral responses into robust, high throughput, high content Phenotypic drug discovery platforms that have led to partnerships with major pharma companies including Eli Lilly, Roche, Sepracor (now Sunovion), and Resilience. There are currently three proprietary platforms, SmartCube®, NeuroCube® and PhenoCube® with new applications and technologies in development. Using its platforms the company can screen tens of thousands of compounds in vivo for potential to treat neuropsychiatric disorders. The Company has several partnered drug discovery programs that have emerged from its technologies and include two Phase II programs, one program in Phase I and 2 more that are expected to go into clinical trials in 2016.

MANAGEMENT
Emer Leahy, Ph.D., President & CEO
Ronald Christopher, Director, Finance
Mark A. Hofer, M.S., J.D., General Counsel
Vadim Alexandrov, Ph.D., Chief Informatics Officer
Taleen Hanania, Ph.D., Sr. V.P., Behavioral Pharmacology
Sylvie Ramboz, Ph.D., V.P., Neurodegenerative Disorders
Afshin Ghavami, Ph.D., V.P., Research Operations
Mukesh Bansal, Ph.D., V.P., Data Science
Christina Leahy, M.S., V.P., Quality Assurance and Vivarium Operations
1st Annual Neuroscience BioPartnering & Investment Forum

Purdue Pharma L.P.
www.purduepharma.com

SECTORS
- Biotechnology • Pharmaceuticals/Licensing

COMPANY PROFILE
Purdue Pharma, a private company founded by physicians, is committed to advancing the medical care of patients with quality pharmaceutical products. We are known for our pioneering research in pain, a principal cause of human suffering. Today, we work with new partners on innovative healthcare solutions in many therapeutic areas.

OPPORTUNITIES
Core: Pain
Adjacency: CNS
New areas: Late stage portfolio build.

MANAGEMENT
Mark Timney, Chief Executive Officer
Jean-Jacques “JJ” Charhon, Chief Financial Officer
Saeed Motahari, Chief Commercial Officer
Gail Cawkwell, MD, Ph.D., Chief Medical Officer
J. Alan Butcher, Head of Licensing and Business Development
Alan W. Dunton, MD, Head of Research & Development
David Lundie, Head of Technical Operations (US) and Technical Operations Director (Rest of World)
Philip C. Strassburger, General Counsel
Bert Weinstein, Chief Ethics & Compliance Officer
Raul Damas, Head of Corporate Affairs and Communications
Susie Robinson, Head of Human Resources
Zachary Perlman, Ph.D., Chief of Staff to the Chief Executive Officer
Edward B. Mahony, Head of Due Diligence & Integration Management
Stuart D. Baker, Counsel to the Board of Directors
Kathryn Gregory, Executive Director, Licensing & Business Development
T3D Therapeutics, Inc.
www.t3dtherapeutics.com

SECTORS
- Biotechnology • Pharmaceuticals/Licensing

COMPANY PROFILE
T3D Therapeutics Inc. is a privately-held, Research Triangle Park, NC region-based company incorporated in 2013 as a Delaware C corporation. T3D Therapeutics’ mission, as a pharmaceutical R&D company, is to develop and commercialize T3D-959, potentially an optimal disease remedial therapeutic for the treatment of Alzheimer’s Disease and Mild Cognitive Impairment. T3D-959 is unlike most therapies in development that target one defect (i.e. pathology), for example beta amyloid plaques or tau bundles. This orally-delivered once-a-day therapy has the potential to be a transformational therapy by treating multiple defects (pathologies) of AD, including a likely key ‘trigger’ for the disease, insulin resistance. As a dual nuclear receptor agonist, T3D-959 may regulate a myriad of genes involved in Alzheimer’s disease pathologies and thus may offer a greater potential to slow, stop or reverse disease progression. T3D-959 has successfully completed Phase 1 human clinical trials and demonstrated compelling and unique pre-clinical efficacy in an Alzheimer’s animal model.

PRODUCT PIPELINE
T3D-959 / Phase 2a
T3D-959 is the lead, small molecule product candidate from the technology package exclusively licensed by the Company. T3D-959 is currently in Phase 2a clinical testing in mild-to-moderate Alzheimer’s patients. The compound is orally delivered as a once-a-day drug therapy.

OPPORTUNITY
T3D-959
T3D-959 is the lead, small molecule product candidate from the technology package exclusively licensed by the Company. T3D-959 is currently in Phase 2a clinical testing in mild-to-moderate Alzheimer’s patients. The compound is orally delivered as a once-a-day drug therapy.
T3D-959 is a potential ‘First in Class’ and ‘Best in Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease (AD), a drug with the potential to slow, stop or reverse the course of disease. Disease reversal has been demonstrated pre-clinically. Early quantitative and qualitative clinical results in Alzheimer’s patients have indicated:
- Potentially superior improvement in cognition to any marketed drug or drug in development
- Potential to improve motor function / coordination
- Effective drug penetration into the human brain
- High safety potential
- A probable low dose range for effectiveness

MANAGEMENT
John Didsbury, Ph.D., CEO
The company is led by Dr. John Didsbury, a seasoned CEO who led the development of T3D-959 at a previous company. Under his leadership T3D-959 went from a lead molecule to an approved IND in under 18 months. Dr. Didsbury has a thorough knowledge of drug development and business with leadership roles spanning 24 years in both public and private small, medium and large pharmaceutical companies.

Stanley Chamberlain, Ph.D., VP Chemistry & Pharmaceutical Development
Formerly CSO at PurThread Technologies, VP of Chemistry at Inhibitex, Inc. and Medicinal Chemistry Mgr. GlaxoSmithKline, Inc.

Hoda Gabriel, PMP. Senior Director Clinical Development.
A certified project management professional, 24y experience. Formerly with GlaxoSmithKline, Inc., Talecris Biotherapeutics and Parexel.

Charles Lineberry, Ph.D., Board Director
30+y experience in clinical drug development and regulatory affairs and former Co-Founder and CEO of Lineberry Research Associates, a full-service CRO and strategic consulting firm.

Barry Buzogany, Esq., Board Director
C-level executive (CEO/COO/CLO) for 25 years for both public and privately-held pharma, life sciences and contract research organizations.

John Golden, Founding Investor and Board Director.
Vaccinex, Inc.
www.vaccinex.com

SUPPORTING ORGANISATIONS
ORGANISERS
PRESENTING COMPANIES
WELCOME
SPEAKERS
PRESENTING COMPANIES
SUPPORTING ORGANISATIONS
ORGANISERS

SECTOR
• Biotechnology

COMPANY PROFILE

Oncology - Vaccinex has discovered and developed an immune-modulating, anti-semaphorin 4D (SEMA4D) antibody that has been shown in preclinical studies to regulate the infiltration of immune cells into the tumor microenvironment. Specifically, anti-SEMA4D induces an increase in tumor-specific cytotoxic T cells and a change in the balance of tumoricidal and regulatory macrophages toward a pro-inflammatory, anti-tumorigenic response. Phase 2 trials are being planned.

Neurology - Vaccinex is investigating the ability to protect neurons from degeneration and to effectively prevent or delay the onset of Huntington’s Disease (HD) by blocking the inflammatory response of astrocytes and microglia as mediated by SEMA4D. In HD, it is thought that chronic activation of astrocytes and microglia, the natural inflammatory cells of the brain, may contribute importantly to the degenerative process in this and other neurological disorders. A phase 2 trial is ongoing.

Drug Discovery - Vaccinex has developed a proprietary platform called ActivMAb to enable the efficient identification of high-affinity, full-length human monoclonal antibodies with built-in manufacturability and favorable biophysical properties ideally suited for downstream development. We took the throughput and flexibility of phage and yeast display and migrated it to mammalian cells. We have used this platform for the discovery and development of human therapeutic monoclonal antibodies to treat serious diseases with unmet needs for internal and external projects.

PRODUCT PIPELINE

<table>
<thead>
<tr>
<th>Research/Preclinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEMA4D Antibody Platform</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VX15 Huntington’s Disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VX15 Melanoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ActivMAb Antibody Discovery Platform</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VX5 Autoimmune Diseases</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NKT Vaccine Platform</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VX25 Immuno-Oncology</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

MANAGEMENT

Dr. Maurice Zauderer, Founder, President & CEO
Steven P. Cobourn, C.P.A., Chief Financial Officer
Raymond E. Watkins, Senior Vice President and Chief Operating Officer
John E. Leonard, Ph.D., Senior Vice President, Development
Ernest S. Smith, Ph.D., Senior Vice President, Research and Chief Scientific Officer

Vaccinex, Inc.
www.vaccinex.com
Supporters

Biotechgate

Biotechgate is a global, comprehensive, life science database covering the Biotech, Pharma and Medtech industries.

There are currently over 36,000 company profiles on the Biotechgate database. Biotechgate is commonly used to find product pipelines, collaboration partners, in/out-licensing opportunities and information about technology platforms, management details, new business leads and financing rounds. In addition, our licensing deals database supports companies in negotiating their licensing agreements.
FreeMind is a consulting group whose goal is to assist its clients in maximizing their potential to receive funding from non-dilutive sources.

Established in 1999, FreeMind is the largest consulting group of its kind with over 400 active clients, academics and Industry alike. FreeMind’s proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date. Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations such as Michael J Fox, Bill and Melinda Gates and Susan G Komen.

FreeMind’s knowledgeable and experienced team of Analysts and Project Managers are dedicated to guiding its clients non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our team of experts will assist our clients in making non-dilutive funding a key tool in their long-term financial strategy.
Instinctif Partners is an international business communications consultancy.

With a track record of delivering truly creative programmes, the Life Sciences practice focuses on enhancing the value proposition for companies seeking investment, partnerships or customers. Our core skill is working with clients to communicate the value of their science and innovation to key stakeholders through the most relevant channels: crafting communications solutions that showcase each company, product or technology. Specifically, we are unique in offering specialist expertise seamlessly across corporate, financial, healthcare and marketing communications with outreach programmes to media, industry, professional, public, financial and investment communities.

Our service offering covers all communications disciplines including strategic counsel, PR, IR, media relations, public affairs, crisis communications, internal communications, marketing, advertising, copywriting, design, research and event management. Our globally integrated and dedicated life sciences team serves clients around the world from our headquarters in London, and bases across Europe, AsiaPac and the USA.
Swiss Biotech

Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, BaselArea, Biopolis Ticino and Greater Zurich Area).

The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services. The National Industry Association named Swiss Biotech Association Represents more than 150 companies to date and acts as the operational arm for the marketing alliance. Swiss Biotech raises Switzerland’s profile as an economic center in Europe and profiles the biotech industry with its key research institutions and companies. Swiss Biotech’s mission is to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of biotechnology including research, education, economics, finance and industry.

The bases for success in biotechnology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid economic growth. More than 40 technology parks throughout the country support the increasingly important and successful TechTransfer process.
Sachs Associates Ltd is a London-based company, which organises and produces securities and emerging markets conferences in association with major exchanges and news agencies. Sachs Associates is dedicated to the highest quality standards in conferencing and, as a result, produces only a limited number of events each year. Sachs Associates investment conferences focus on Emerging Markets, European Equities and Technology, and are held in major financial centres such as London, New York and Zurich. Sachs Associates is focused on the practical benefits accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions.

The benefits of conference participation with Sachs Associates may be summarised as follows:

Multimedia Exposure
Sachs Associates is uniquely able to provide its conference sponsors maximum exposure across extremely well focused electronic and print media. Regular extensive coverage of all the Company’s conferences is carried out through video streaming and extensive events coverage through major international financial news agencies, including Bloomberg, Dow Jones and Reuters. In addition, Sachs Associates has a number of long established relationships with other financial press organisations globally, which allow further effective distribution on behalf of its clients.

Eminent Speakers
Sachs Associates is committed to ensuring that its events continue to provide forums with the participation of the most eminent speakers from the public and private sectors. Through its reputation and its long-established local relationships, the Company has attracted very senior political and economic personalities as speakers at its events.

Sponsorship and Marketing Opportunities for forthcoming events
Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market.

Sponsorship of any of our events allows you to raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.

The following sponsorship and marketing opportunities are available at future conferences:
• Conference Sponsor – including workshops and social events
• Exhibition stands
• Distribution of Promotional Material

If your company is interested in exhibiting or sponsorship opportunities please call Silvia Kar on +44 203 463 4890.
We look forward to seeing you at:

4th Annual
Cancer BioPartnering & Investment Forum
Focusing on Advances in Immuno-Oncology
24th February 2016 • New York Academy of Sciences • USA

9th Annual
European Life Science CEO Forum & Exhibition
Partnering & Investing In Biotech & Pharma Industry
15th – 16th March 2016 • Hilton Zurich Airport Hotel • Switzerland

2nd Annual
Immuno-Oncology: BD&L and Investment Forum
3rd June 2016 • Hyatt Chicago Magnificent Mile • USA

4th Annual
MedTech & Digital Health Forum
For Technology & Healthcare Innovation
26th September 2016 • Congress Center Basel • Switzerland

16th Annual
Biotech in Europe Forum
For Global Partnering & Investment
27th – 28th September 2016 • Congress Center Basel • Switzerland

For more information about all our events please visit www.sachsforum.com